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ABSTRACT
Persistent Oral Dyskinesias Iduced by Long-Term Haloperidol 
Treatment Is Dissociated from Changes in Neostriatal 
Bb>x and mRNA Content for Dopamine Da Receptors
by
Nuyou Huang
Due to the presumed associations of dopamine (DA) 
receptor supersensitivity phenomena in both long-term 
neuroleptic-treated tardive dyskinetic rats and neonatal 6- 
hydroxydopamine (n6-0HDA)-lesioned rats, we studied the 
influence of haloperidol on n6-OHDA-lesioned rats. At 3 
days after birth rats received 6-OHDA-HBr (200 pig, bilateral 
intracerebroventricularly; desipramine pretreatment, 20 
mg/kg, i.p., 1 h) or vehicle. Two months later haloperidol 
(1.5/kg/day x 2 days/week for 4 weeks, then 1.5 mg/kg/day, 
every day for 10 months) was added to the drinking water. 
Spontaneous oral activity of intact and nS-OHDA-lesioned 
rats receiving haloperidol was reached and maintained at 
significantly higher levels after 15 weeks of haloperidol 
treatment. Haloperidol treatment produced greater oral 
activity in n6-0HDA-lesioned rats as compared to intact 
rats. At 11 months there were 35.8±4.9 vs 18.4±2.1 oral 
movements in lesioned vs. intact rats receiving haloperidol. 
This high level of spontaneous oral activity was not 
attenuated by scopolamine and persisted in the lesioned rats 
for at least 8 months after haloperidol withdrawal. Reverse 
transcription polymerase chain reaction (RT-PCR) analysis of 
alternatively-spliced isoforms of DA Da (Das and DaL) 
receptors showed that DaL receptor mRNA levels of intact and 
n6-OHDA-lesioned rats receiving haloperidol were 
significantly elevated after 11 months of treatment and 
returned to normal level 8 months after haloperidol 
withdrawal. Similarly, the B*** for [3H] raclopride binding 
to striatal homogenates was significantly increased in 
intact and n6-0HDA lesioned rats receiving chronic 
haloperidol. The Baax was at the control level after 8 
months of haloperidol cessation. Das and 5-HTac receptor 
mRNA levels were not altered by chronic haloperidol 
treatment. The effects of assorted receptor-specific drugs 
on oral activity were tested in our rats to study possible 
mechanisms underlying the regulation of oral activity. The 
findings of this study demonstrate that alterations at mRNA 
and receptor levels of DA Da receptors are not critical for 
maintaining persisting enhanced oral dyskinesias after long­
term haloperidol treatment. The long-lasting stable high 
frequency of oral dyskinesias after haloperidol withdrawal 
in these rats provides a means for testing agents that have 
the potential to attenuate dyskinetic oral activity.
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Introduction
A. Central Dopamine Systems
Soon after the discovery of dopa decarboxylase enzymes 
dopamine (DA) was identified as an intermediate in the 
catecholamine synthesis pathway (Holtz et al., 1938). In 
1958 Carlsson and colleagues correctly proposed that DA 
serves not only as a precursor of norepinephrine (NE) and 
epinephrine (Epi) synthesis, but also as a neurotransmitter 
in the brain (Carlsson et al., 1958). There are far more DA 
neurons than other catecholamine neurons in brain. In terms 
of the functional and anatomical organization, brain DA 
systems can be classified as follows (Ganong, 1991,* Cooper 
et al., 1991):
1. The ni gros tria tal dopaminergi c sys tern .*
DA cell bodies in the pars compacta of the substantia 
nigra have axonal projections to basal ganglia in the 
forebrain. This extrapyramidal system has a major role in 
regulating fine motor control. The destructive loss of 
nigral DA cells is correlated with a Parkinsonian syndrome.
2. The mesocortical dopaminergic system;
DA cell bodies in the ventral tegmental nucleus and 
portions of the substantia nigra have axonal projections to 
the limbic cortex. This system is considered to have a major 
role in modulating thinking patterns and motivational state. 
An imbalance of this system might be expressed as neurosis,
1
psychosis or schizophrenic state.
3, The tuheroinfundibular, incertohypothalamic, and 
periventricular dopaminergic system;
Cell bodies of these three DA systems arise in or near 
the hypothalamus and have short axonal projects to adjacent 
brain regions, like the median eminence. DA, released by 
the tuberoinfundibular system, is the primary inhibitory 
regulator of prolactin hormone release. Other pituitary 
hormones, including growth hormone, are influenced in part 
by this DA system.
B. Dopamine Receptors and Behavior
DA receptors can be broadly classified into presynaptic 
receptors (autoreceptors) and postsynaptic receptors. 
Autoreceptors exist in most portions of DA cells such as the 
soma, dendrites and nerve terminals. Somatodendritic 
autoreceptors regulate the firing rate of dopamine neurons 
while terminal autoreceptors regulate the synthesis and 
release of DA. Therefore, autoreceptors can be defined as 
synthesis-modulating, release-modulating and impulse- 
modulating autoreceptors in terms of their functional roles 
(Cooper et al., 1991). Postsynaptic DA receptors are 
located postsynaptically to DA-releasing cell types.
The cDNAs of five DA receptor subtypes have been cloned 
(Sibley et al., 1993; Gingrich and Caron, 1993; Zhang et 
al., 1994). The most popular classification of DA receptors 
divides these five receptor subtypes into Dx-like receptors
and Da-like receptors, on the basis of their biochemical 
characteristics (Kebabian and Caine, 1979; Breese and 
Creese, 1986; Seeman and Van Tol, 1994).
1, Dx-like receptors:
D^like receptors include Dx and D( subtypes. When DA 
binds to these receptors on postsynaptic neurons, there is 
generally an increased intracellular synthesis of cyclic 
adenosine monophosphate (cAMP) (Kebabian and Caine, 1979) .
2. D3-like receptors:
Dj, Da and D4 DA receptor subtypes fall into the Da-like 
receptor category. DA stimulation of these receptors 
generally inhibits the activity of adenylate cyclase and 
thereby reduces synthesis of intracellular levels of cAMP 
(Kebabian and Caine, 1979) . Da receptors trigger signal 
transduction pathways in many ways that are different from 
that of Dt receptors. In addition to their ability to 
inhibit the activity of adenylate cyclase, cloned Da 
receptors are able to stimulate phosphatidylinositol 
turnover (Vallar et al., 1990), regulate K* and Ca3* channel 
activity (Vallar et al., 1990; Castellano et al., 1993) and 
increase arachidonic acid release (Kanterman et al., 1991). 
Autoreceptors can be classified into D,-like receptors in 
terms of their biochemical and pharmacological 
characteristics (Cooper, 1991).
Behavioral studies of dopaminergic systems was 
initiated by Randrup and co-workers about 30 years ago
(Randrup et al., 1965). The availability of relative 
specific DA receptor ligands enabled functional studies of 
the behavioral roles of DA receptor subtypes. The overall 
body of evidence suggests that DA Dt and D, receptors are 
associated directly or indirectly with the mediation of 
behavior responses (Andersen and Nielsen, 1966). Central DA 
systems play important roles in the regulation of motor 
activities and mental functions (Ganong, 1991). Motor 
behaviors are usually considered to be under the control of 
nigrostriatal DA pathway (Ungerstedt and Arbuthnott, 1970; 
Ungerstedt, 1971) while mesolimbic and mesocortical DA 
pathways regulate emotional and reward behaviors (Creese and 
Iversen, 1973). The dysfunctions of nigrostriatal and 
mesocortical dopaminergic systems are linked to Parkinson's 
disease and schizophrenia, respectively (Ganong, 1991; 
Stevens, 1973). DA agonists and antagonists are effective 
agents in the treatment of these two types of neuronal 
disorders.
C. Neonatal 6-hydroxydopamine (n6-0HDA) Treatment and 
Supersensitivity of Central DA Systems
Removal of neuronal input is one of the important means 
to study the functions of a particular neuronal system 
(Kostrzewa and Jacobowitz, 1974). The remarkable discovery 
of Tranzer and Thoenen revealed that 6-OHDA, an isomer of 
NE, selectively destroyed peripheral catecholamine- 
containing neurons (Tranzer and Thoenen, 1967; Tranzer and
Thoenen, 1968). When adrenergic neurons are protected by 
desipramine pretreatment, 6-OHDA produces a selective 
lesion o£ the DA system (Breese and Traylor, 1972). Upon 
stimulated by DA agonists, behavioral responses, such as 
stereotyped behavior, locomotor and oral activities, are 
greatly enhanced in n6-OHDA-lesioned rats. This evidence 
indicates that central dopaminergic systems are 
supersensitized by n6-0HDA treatment (Breese et al., 1984; 
1985a,1985b; 1987; Kostrzewa and Hamdi, 1991; Kostrzewa and 
Gong, 1991; Hamdi and Kostrzewa,1991, Gong et al., 1992, 
Kostrzewa and Neely, 1993).
D. Neonatal 6-OHDA Treatment and Number of DA Neurons in Rat 
Brain
Using an antibody to tyrosine hydroxylase (T-OH) Berger 
et al. (1985) found that the number of T-OH immunoreactive 
(THIR) cell bodies in pars compacta of the substantia nigra 
were too numerous to count in intact rats.. They estimated 
>4000 THIR cells in this nucleus. In contrast, in n6-0HDA- 
lesioned rats (150 fig 6-OHDA, base) there were only 12 to 
110 THIR remaining cells in this nucleus (mean of 63 cells). 
Similarly, unilateral intrastriatal injection of 6-OHDA (8 
M9) on postnatal day 2 (P2) caused a significant retrograde 
degeneration of THIR neurons in the substantia nigra of the 
lesioned side at F9 and P22 (Cabothe et al., 1991).
Bilateral intracerebroventricular (icv) injection of 6- 
OHDA (100 fig each side) resulted in a marked loss of THIR
neurons in mesencephalon. The loss of THIR neurons was more 
severe in the substantia nigra pars compacta and in the 
ventral A9 cell group of the A9 complex while the A10 region 
and the lateral cell group of the A9 complex were less 
severe by affected (Luthman et al., 1990a). Yokoyama et al. 
(1993) reported that intracisternal injection of 6-OHDA (67 
fig) on PI induced degeneration of THIR neurons. The 
decrease of immunoreactive intensity and the appearance of 
dot-like THIR processes, was first found in the substantia 
nigra 12 h after the injection of 6-OHDA. The 
immunoreactive neurons at the substantia nigra were 
marginally detected 96 h after 6-OHDA. In contrast to the 
DA neurons at the substantia nigra, there was no detectable 
degeneration of THIR neurons or terminals in the 
hypothalamic arcuate nucleus and in the median eminence at 
least 96 h after the injection of 6-OHDA. In addition, when 
n6-OHDA-lesioned rat brain tissues were analyzed at 2-5 
months after birth, it was found that intracisternal 
injection of 6-OHDA (67 fig) on PI or unilateral 
intraparenchymal injection of 6-OHDA (8 fig on P3) produced 
almost complete depletion of THIR neurons in the substantia 
nigra and striatum. Less extensive changes of THIR neurons 
were found in the ventral tegmental nucleus, arcuate nucleus 
(A12), zona incerta (A13), periventricular area (A14) and 
posterior hypothalamic area (All). In order to exclude the 
possibility that the difference in regional 6-OHDA
7concentrations by intracisternal injection may contribute 
to the difference in the sensitivity of substantia nigra and 
hypothalamic THIR neurons to 6-OHDA toxicity, the same dose 
of 6-OHDA was injected at PI by different routes (intra­
lateral or third ventricles), Similarly, the degeneration of 
THIR neurons and fibers was found only in the substantia 
nigra and caudate putamen, not in the hypothalamus. 
Therefore, it is unlikely that the difference in 
sensitivity to 6-OHDA is due to a difference in the regional 
concentration of 6-OHDA (Yokoyama et al., 1993).
Differences in uptake-accumulation and/or intraneuronal 
factors that interfere with the auto-oxidation reaction of 
6-OHDA may be responsible for differences in sensitivity to 
6-OHDA (Jonsson, 1983). There are 2 to 3 times more high 
affinity dopamine uptake sites in nigrostriatal DA neurons 
than in tuberoinfundibular DA neurons (Annunziato et al., 
1980) .
E. Neonatal 6-OHDA Treatment and DA Uptake Sites 
Using quantitative autoradiography (QAR) with 
[3H]mazindol as the ligand for high-affinity DA uptake sites 
(a DA terminal density marker), it was found that the 
developmental pattern for DA uptake sites was parallel to 
that of DA receptors. That is, patch compartments developed 
at an early stage in life and this was followed by 
maturation of the matrix compartment (Rao et al., 1991). 
Bilateral intrastriatal injection of 6-OHDA (4, 8, or 20 fig
each side) at PO or PI resulted in an extensive alteration 
in the number of DA uptake sites {Neal and Joyce* 1991,
1992; Neal-Beliveau and Joyce, 1993). n6-0HDA-lesions caused 
a dose-dependent patchy loss of high affinity DA binding 
sites (Neal-Beliveau and Joyce, 1993), There was an overall 
22-75% reduction of [3H]mazinol binding sites in the 
striatum of the nS-OHDA-lesioned rats at low dose (4 /ig each 
side) and intermediate dose (8 fig each side), whereas the 
high dose (20 fig each side) caused almost complete loss of 
[JH]mazindol binding sites (Neal-Beliveau and Joyce, 1993). 
The most extensive loss of [’Hlmazindol binding sites was in 
the dorsomedial quadrant of the left striatum which showed a 
43% loss of binding sites. Accumbens septi (NAS) was less 
affected, there being a loss of only 15% of binding sites 
(Neal and Joyce, 1992).
F. Neonatal 6-OHDA treatment and DA receptor mRNA
In situ hybridization and autoradiographic studies 
showed that DA Da receptors are detectable at PI in the 
caudate-putamen. Dt receptors density reaches adult levels 
at P16. The development and maturation of Da receptors 
occurs later, DA D3 receptor binding can not be observed 
until P3 in the striatum and not until P7 in the globus 
pallidus and substantia nigra. The density of D, receptors 
approaches adult level between P16 and P30 (Rao et al.,
1991). Using slot bolt and in situ hybridization as tools, 
it was reported that D, mRNA was detectable in striatum on
the day of birth, then increased gradually and reach peak 
levels at P16. The different peak time for slot blot and in 
situ hybridization may be due to the difference of Da mRNA 
expression at the subpopulations of the neurons. Similar to 
the DA receptor binding characteristics, the distribution of 
Da mRNA also showed a lateral to medial gradient in the 
striatum. Ontogenetic development of Da receptor mRNA was 
reported to be correlated to the expression of Da receptor 
(Chen and Weiss, 1991). In another study using polymerase 
chain reaction (PCR) techniques, it was reported that whole 
rat brain Da receptor (DSJW44 and DaA41s receptors) mRNA was 
measurable at P14 and day P17 respectively and then 
increased to the adult level {Mack et al., 1991). In this 
study mRNA was not detected prior to P14. The possible of 
the expression of Da receptor mRNA prior to P14 can not be 
excluded. Therefore, there are dramatic ontogenetic changes 
in striatal Dt and Da receptor densities and their mRNA 
levels. Dt and Da receptor densities and mRNA levels 
increase after birth until P15 to P30, then decline slightly 
(Chen and Weiss, 1991; Mack et al., 1991; Xu et al., 1992).
The daily treatments of intact rats with SKF 38393 
[(±)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol 
hydrochloride, 3.0 mg/kg/day, i.p.], for the first 28 days 
from birth did not alter the expression of Dt mRNA in rat 
striatum when analyzed at 11 weeks of age. Similar 
ontogenetic SKF 38393 treatment of neonatal 6-OHDA-lesioned
rats (67 fig in each lateral ventricle at P3) significantly 
reduced rat striatal DA Dt mRNA level. However, the level of 
DA Di mRNA was restored by 4 weekly SKF 38393 treatments 
(3.0 mg/kg/day, i.p) during the 6th through the 9th weeks 
after birth (Gong et al., 1994}. It has been reported that 
the presence of dopaminergic neurons is required for the 
normal expression of Dt receptors (Saleh and Kostrzewa,
1989). Also the loss of DA D1 and Da receptor sites has 
been found after a neonatal 6-OHDA-lesion (Deskin et al., 
1981; Gelbard et al., 1990). These series of studies suggest 
that endogenous DA might be important for the development of 
DA receptors (Gelbard et al., 1990; Saleh and Kostrzewa, 
1989).
In other investigations the ontogenetic development of 
central DA systems was impaired either by icv injection of
6-OHDA (134 g^) on P3, daily injection of the Da receptor 
antagonist SCH 21390 [R-(+)-7-chloro-8-hydroxy-3-methyl-l- 
phenyl-2,3,4,5-tetrahydro-lH-3-benzazepine hydrochloride, 
0.25 mg/kg/day, i.p.) from P4 to P20, or the combined 
treatments with 6-OHDA and SCH 23390. When analyzed at P21, 
it was found that none of these three treatments was able to 
alter the level of DlA receptor mRNA in both caudate-putamen 
and the nucleus accumbens. There was also no alteration in 
Da receptor binding ([3HJSCH 23390) (Duncan et al., 1993). 
Similarly, striatal Da mRNA levels in the brain of 16 and 32 
day old rats was not altered by n6-OHDA (bilateral icv, 67
fig each side) treatment at P3 and P6 (Chen and Weiss* 1991) . 
Striatal Da mRNA was found significantly increased (15%) 
after high dose of bilateral icv 6-OHDA treatment (150 (tg 
each side) at P3 as assessed at 60 days after birth. The 
increase of D3 mRNA was more obvious in the lateral than in 
the medial striatum. Lower dose of 6-OHDA (67 fig) did not 
cause change in D3 mRNA level (Soghomonian, 1993). These 
findings do not support the view that dopaminergic input is 
a critical factor for postnatal ontogenetic expression of DA 
mRNA* although it is possible that central DA systems may be 
involved in striatal DA receptor development prior to n6- 
OHDA treatment. More work is needed to clarify the 
relationship between ontogenetic dopaminergic input and the 
expressions of DA receptor mRNAs and their proteins.
Q. Neonatal 6-OHDA treatment and DA receptors
Autoradiography studies with specific ligands have 
revealed the ontogenetic developmental characteristics of DA 
receptors (Rao et al., 1991; Cabeche et al., 1991; Murrin 
and Zeng, 1989). Using ['HJSCH 23390 as a ligand, clear 
heterogeneous patchy binding was found in rat striatum at 
PI, most obviously in the rostrocaudal extension of the 
lateral two-thirds of the striatum. At P3 and P4, the patchy 
distribution of [*H]SCH 23390 binding was observed in the 
whole latero-medial and rostro-caudal extension of the 
striatum. The distribution of Dt patches was parallel to 
that of the THIR staining. Beginning from P9, there was
dissociation between the relative distribution of [3H]SCH 
23390 binding and THIR staining. Patchy binding was 
observed only in the ventral part, not the dorsal part of 
the striatum at this age. However, THIR fibers were present 
to a greater extent in the dorsal vs. ventral striatum. By 
22 days after birth [JH]SCH 23390 binding and THIR staining 
were found homogeneously distributed in the whole striatum. 
(Caboche et al., 1991). This suggests that there is a 
separate organization of patchy and matrix compartments 
during development. The density of Dt receptor was 16% of 
the adult level at PI and reached 38% at P10. Afterwards, 
there was a dramatic elevation of Dt density between P10 to 
P16. In contrast, the development characteristics of D2 
receptors is different from that of Dt receptors. D, 
receptors were not detectable until P3 and reached the adult 
level between P16 to P30 (Rao et al., 1991). These 
differences in the ontogenetic development of these DA 
receptor subtypes may give rise to their difference of 
vulnerability to 6-OHDA toxicity. Therefore, the time at 
which neonatal lesion is performed may be critical for 
changes in DA receptor subtypes.
The effects of n6-OHDA depletion on central DA systems 
and DA receptors are highly controversial. It was found 
that DA receptors were unaltered (Breese et al., 1987; Dewar 
et al., 1990; Hamdi and Kostrzewa, 1991; Kostrzewa and 
Hamdi, 1991; Caboche et al., 1991;), decreased {Duncan et
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al., 1987; Dewar and reader, 1989; Neal and Joyce, 1992; 
Neal-Beliveau and Joyce, 1993; Radja et al., 1993) or 
increased (Broaddus and Nennett, 1990) in adult rats after 
the depletion of central DA systems with n6-OHDA treatment.
In a study involving nS-OHDA treatment {67 fig, 
intracisternally) of rats at P3, autoradiography with the DA 
Di ligand [3H]SCH 23390 revealed no change from control, of 
[JH]SCH 23390 binding in dorsolateral striatum, dorsomedial 
striatum, ventrolateral striatum, ventromedial striatum and 
nucleus accumbens (Simson et al., 1992). When rats were 
observed at P9 and P22, Caboche et al. (1991) demonstrated 
that unilateral intrastriatal injection of 6-OHDA (8 fig) at 
P2 did not cause any alteration in the [3H] SCH binding 
pattern and density at lesioned and unlesioned sides of 
ventral, dorsal and whole striatum. This treatment resulted 
in a significant decrease of THIR fibers in the striatum and 
a retrograde degeneration of THIR neurons in the substantia 
nigra. Because of the dissociations between THIR fiber 
distributions and [JH]SCH 23390 binding patterns, the 
authors suggested that ontogenic development of Dt receptors 
may not be depend upon the presynaptic DA elements (Caboche 
et al., 1991).
In contrast to the above results, bilateral 
intrastriatal injection of 6-OHDA (4, 8, or 20 fig each side) 
at P0, PI or P2 produced significant loss of [3H]SCH 23390 
binding of Dx receptors in the striatum. This patchy
reduction of Dt receptor binding was not dose-dependant. The 
loss of D3 binding was preferential to the dorsomedial 
caudate-putamen (CPu) and the patchy compartment. In 
contrast to the changes in Dx receptor subtypes, this 
treatment did not cause a significant alteration in striatal 
Da receptor number. Although the reduction of D3 receptor 
binding density was greater in the medial CPu than that in 
the central and lateral CPu regions, the normal lateral to 
medial gradient D3 binding characteristic in the striatum 
was not altered by intrastriatal n6-0HDA treatment. The 
absence of change in D, receptors may due to the fact that 
Da receptors are not present in the striatum at the time of
6-OHDA treatment (Neal and Joyce, 1992; Neal-Beliveau and 
Joyce, 1993). Radja and associates (1993) reported that 
bilateral icv injection of 6-OHDA (50 (ig each side) at P3 
caused significant changes in both Dx and D3 receptors as 
determined by autoradiography. Dt receptor binding (['HJSCH 
23390) in the rostral striatum was significantly decreased 
whereas there was no marked alteration in the caudal 
striatum. DA D3 receptor binding ([*H] raclopride) was 
significantly increased (23-27%) in all parts of the caudal 
striatum and most parts (dorsolateral, dorsomedial and 
ventrolateral) of rostral striatum (except ventromedian 
quadrants of the rostral striatum). In the substantia 
nigra, the density of D3 binding was dramatically (80%) 
elevated. In situ hybridization study revealed that there
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was no alteration in the amount of D, receptor mRNA in the 
striatum of n6-0HDA-lesioned rats vs control rats.
Using tJH] raclopride as a ligand, Dewar et al (1990) 
found that n6-0HDA treatment was not associated with an 
alteration in Bn>x or Kd for DA Da receptors in the rostral 
striatum at 15 days and 1 month of age. However, at 3 
months the was increased by 25%. In caudal striatum the 
Bn„x and Kd of [3H] raclopride binding did not change at these 
intervals after n6-OHDA treatment. Broaddus and Bennett 
(1990) applied 3 different protocols for the n6-0HDA lesion 
to obtain selective damage of DA systems: (1). Bilateral 
intrastriatal (i.s.) injection of 6-OHDA (20 /ig) at P2 to 
cause selective destruction of the 'patches'; (2). Four 
weekly (1 to 4 weeks) injections (i.s.) of 6-OHDA (20 fig) to 
destroy DA terminals in both patchy and matrix systems; (3). 
Intracisternal injection of 6-OHDA (120 fig) at P3 to cause 
extensive damage .of midbrain DA neurons. It was found that 
all these treatment protocols resulted in an increase (15- 
40%) in the BnaK of SCH 23390 binding in the striatal 
homogenates. The first and second protocols also led to an 
increase of Kd for SCH 23390 binding to Dx receptors. This 
may implicate a depletion supersensitivity of Dt receptors. 
However, these lesion protocols decreased Da receptor 
density (B..^) in the striatal homogenates, using [JH] {-) 
sulpiride as ligand. These results indicate that the 
development of Da receptors is probably regulated by DA
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innervations (Broaddus and Bennett, 1990).
Receptor binding studies indicate that n6-OHDA 
treatment supersensitizes DA Dx receptors without altering 
Dx receptor density (Bmjut) and affinity (Kd) (Hamdi and 
Kostrzewa, 1991; Luthman et al., 1990b; Duncan et al.,
1967). It is known that DA Dl receptors have high and low 
affinity states of agonist binding (Leff et al., 1985;
Seeman et al., 1985). No change in the distribution of D1 
receptor high and low agonist binding sites was found in n6- 
OHDA-lesioned rats (Gong et al., 1994).
The mechanisms underlying the changes in DA receptors 
after n6-OHDA are still unclear. It was proposed that the 
depletion of endogenous DA may contribute to the DA receptor 
changes after n6-0HDA treatment (Gelbard et al., 1990). It 
was found that in intact rats, there was a negative 
correlation between the densities of DA receptor binding 
and the levels of DA in forebrain tissue. This' inverse 
correlation was eliminated by daily administration of 
exogenous DA (SKF 38393). Similarly, the changes of D, 
receptor binding induced by n6-0HDA treatment was restored 
by SKF 38393. These findings indicate that there is an 
important role of endogenous DA in regulating Dt receptor 
development (Gelbard et al., 1990). In adult animals, 
transplantation of fetal mesencephalic DA neurons did not 
reverse the loss of DA receptors (Blunt et al., 1992). The 
developmental stage at which the central DA system is
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depleted is an important determinant of the changes in DA 
receptors by nG-OHDA treatment (Neal and Joyce., 1992; Neal- 
Beliveau and Joyce., 1993). Furthermore, DA receptor ' 
supersensitization in n6-OHDA-lesioned rats can not be 
simply explained by changes in either DA receptor binding 
parameters or the expressions of DA receptor mRNAs. It has 
been suggested that an imbalance among DA, 5-HT and other 
neurotransmitter systems underlies the phenomenon of DA 
receptor supersensitivity (Gong et al., 1994; Kostrzewa and 
Neely, 1993, Kostrzewa, 1995).
H. Anatomy of Central Serotonin Pathways
Serotonin (5-HT) was isolated and synthesized and its 
chemical structure was defined in late 40's and early 50's 
(Hamlin and Fisher, 1951; Rapport, 1949; Rapport et al., 
1948). The significant abundance of 5-HT in various regions 
of the central nervous system (CNS) suggests that it is a 
major CNS transmitter (Amin et al., 1954), The discovery of 
the involvement of 5-HT in the major psychoses (Jacobs,
1984) led to a great deal of interest in this 
neurotransmitter. Although the numbers of 5-HT cells in the 
CNS constitute only about 1/1,000,000 of all CNS neurons, 
the influence and regulation of 5-HT systems on their target 
sites seem to be much greater than their numbers (Jacobs and 
Azmitia, 1992)
The 5-HT neurons can be defined into superior and 
inferior groups that are located in the brain stem around
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the midline {Jacobs and Azmitia, 1992). Projections of 5-HT 
axons from cell bodies in the dorsal and medial raphe 
located in the midbrain innervate various regions of the 
brain such as substantia nigra, striatum, mesolimbic system, 
hippocampus, hypothalamus and forebrain region (Meltzer and 
Nash, 1991).
5-HT projections to substantia nigra and striatum are 
originate from the rostral potion of the dorsal raphe (Imai 
et al., 1986; Molliver, 1987). Afferent 5-HT fibers from 
both dorsal and medial raphe innervate mesolimbic regions 
such as the ventral tegmentum (Simon et al., 1979; Parent et 
al., 1981). Medial raphe 5-HT neurons project to the 
hippocampus (Moore and Halaris, 1975). 5-HT fibers arising 
from both the dorsal and medial raphe pass through the 
hypothalamus and innervate forebrain regions (Meltzer and 
Nash, 1991).
I. Serotonin Receptors and their Functional Roles
The latest classification of Serotonin Club Receptor 
Nomenclature Committee defined 5-HT receptors into seven 
classes base on three fundamental properties: operational 
(drug-related), transductional (receptor-coupling) and 
structural (primary amino acid sequence) characteristics 
(Humphrey et al., 1993; Martin and Humphrey, 1994). The 
characteristics of each 5-HT receptor class are outlined as 
follows:
1. The 5-HT1 receptor
19
Five 5-HT receptor subtypes are recognized as 5-HTi 
receptors. These include 5-HT1A, 5-HT1B, 5-HT10, 5-HT1B and 5- 
HTlP. They all have seven transmembrane (TM) domains and 
are linked to the inhibition of adenylate cyclase (Martin 
and Humphrey* 1994) .
a. 5-HT1A receptors
This subtype of 5-HT receptors is located primarily in 
the limbic system, with a lesser extent in dorsal and median 
raphe nuclei. These regions regulate mood, anxiety, 
temperature, feeding and locomotion. 5-HTlx receptors are 
important for the action of antipsychotic drugs (Meltzer and 
Nash, 1991; Martin and humphrey, 1994).
b. 5-HT1B receptors and 5-HT1D receptors
5-HT1B receptors are unique in rats and some other
rodents. These receptors are not present in humans. The
exact physiological functions of 5-HT1B and 5-HT1D receptors 
are not clear, because of the lack of specific ligands.
They may function either as autoreceptors or regulate the 
release of acetylcholine, glutaminate or other 
neurotransmitters.. Substantia nigra and basal ganglia are 
two areas with the highest densities of 5-HT1B and 5-HT1D 
receptors (Engel et al., 1986, Maura and Raiteri, 1966).
c. 5-HTia and 5-HTlp receptors
The distribution of 5-HT1B receptors is similar to that
of 5-HT1D receptors in the CNS (Leonhardt et al., 1969).
However, unique distributions of 5-HTlp receptors, which
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include the pyramidal cells of the cortex and, the dorsal 
raphe and the hippocampus, have been revealed (Amiaiky at 
al., 1992; Martin and humphrey, 1994). The physiological 
roles of these two receptor subtypes are yet to be 
determined. There are still no selective ligands for these 
receptor subtypes.
2. 5-HT3 receptor
5-HTa receptors consist of three subtypes, namely 5- 
HTaA, S-HTaB and 5-HTac receptors. They all have seven TM and 
are coupled to phospholipase C and increased production of 
IPj (Hoyer et al., 1994,; Martin and Humphrey, 1994).
a. 5-HTiA and 5-HTaa receptors
5-HTja receptors exist primarily in cortex, and to a 
lesser extent in hippocampus and caudate nuclei (Hoyer et 
al., 1986). These receptor subtypes are known to have 
regulating roles for motor activity and sleep (Sharpley et 
al,, 1990). 5-HTaa receptors are found only in peripheral 
tissues, such as the stomach fundus (Kursar et al., 1992).
b. 5-HTjC receptors
5-HTac receptors distribute with highest density in 
choroid plexus and to a lesser extent in the limbic system, 
basal ganglia, hypothalamus and hippocampus (Pazos et al., 
1987: Julius et al., 1988; Molineaus et al., 1989). 5-HTac 
receptors have been proposed as having a regulating role for 
oral activity (Gong et al., 1992; Kostrzewa and Gong, 1991), 
locomotion, eating and anxiety (Kennett and Curzon, 1988;
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Kennett et al., 1989; Lucki, 1992).
3. 5-HT3 receptor
5-HT, receptors are structurally and functionally 
distinct from all other 5-HT receptors. In fact, these 5-HT 
receptors are ligand-gated cation channels {Martin and 
Humphrey, 1994). In the CNS 5-HT, receptors are found in 
the area postrema, the nucleus tractus solitarius, the 
dorso-vagal complex and the trigeminal nucleus caudalis 
(Waeber et al., 1988; Kilpatrick et al., 1990). 5-HT,
receptors modulate the release of other neurotransmitters 
such as DA (Blandina et at., 1988) and r-aminobutyric acid 
(GABA) (Alhaider et al., 1991).
4. 5-HT4 receptors
The structure of 5-HT4 receptors is currently unknown.
In the CNS, activation of 5-HT4 receptors in the hippocampus 
elevates the formation of cAMP (Dumuis et al., 1988) and 
decrease K* conductance (Andrade and Chaput, 1991). It was 
shown that 5-HT4 receptors are also localized in the 
striatum, substantia nigra and olfactory tubercle of rats 
and guinea-pigs. However, the functional role of 5-HT4 
receptors remains to be determined (Grossman et al., 1993).
5. Other 5-HT receptors
5-HT,, 5-HT,, and 5-HT7 receptors are the newest numbers 
of the 5-HT receptor family. Their genes were cloned 
recently (Plassat et al., 1993; Monsma et al., 1993; Ruat et 
al., 1993). It has been proposed that 5-HT, receptors
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feature seven TM and are coupled to G-protein. Their second 
messenger system is unknown. Very little is known about the 
functional roles of 5-HT,, 5-HT, and 5-HT, receptors (Martin 
and Humphrey, 1994).
J. Neonatal 6-OHDA Treatment and 5-HT Fiber Sprouting in Rat 
Striatum
The 5-HT content of the striatum of rats treated 
neonatally with 6-OHDA (100-200 fig; desipramine 
pretreatment) has been found to be elevated by 50 to >100% 
(Breese et al., 1964; Stachowiak et al., 1964). A 20% 
reduction in size of the striatum could not account for the 
elevation in striatal 5-HT content in n6-0HDA-treated rats. 
Further study revealed that 5-HT content of caudal striatum 
remained unchanged whereas 5-HT content of rostral striatum 
was elevated as much as 4 to 5-fold (Stachowiak et al. , 
1984; Dewar et al. , 1990). The elevation in 5-HT content 
of rostral striatum was accompanied by a proportionate 
increase in the [3H]5-HT accumulation by striatal 
homogenates (Stachowiak et al. , 1984). These findings 
indicated that the loss of DA innervation of the striatum 
did not influence the 5-HT fiber innervation of caudal 
striatum, which has a 5-HT content and 5-HT fiber input that 
is 3 to 6 times that of rostral striatum. However, the loss 
of DA input to the striatum seemed to induce heterotypic 
sprouting and hyperinnervation of rostral striatum by 5-HT 
fibers.
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Using an antibody to 5-HT, it was shown that n6-0HDA 
treatment was associated with a several-fold increase in the 
number of 5-HT-immunoreactive (IR) fibers in rostral 
striatum. The fine and highly varicose fibers increased in 
number by only a slight amount in caudal striatum {Snyder et 
al., 1986; Luthman et al., 1987).
The change in 5-HT content in rostral striatum of n6- 
OHDA rats was not accompanied by a change in 5-HT content of 
the olfactory tubercle or septum (Stachowiak et al., 1984), 
nor frontal cortex, occipital cortex, mesencephalon, raphe 
nucleus or cerebellum (Luthman et al., 1987). A 30% 
increase in 5-HT was measured in the cingulate cortex, 3 
months after n6-0HDA (Dewar et al., 1990). Numbers of 5- 
HTIR fibers in the basal forebrain, septum, cortex and 
substantia nigra were also not altered (Snyder et al.,
1986).
K. Neonatal 6-OHDA treatment and 5-HT Receptors
In the striatum of intact and n6-OHDA-lesioned rats 5- 
HT1A receptors are not present. The low numbers of 5-HT1B 
and 5-HT,A receptors were increased in the rostral striatum 
of n6-OHDA-lesioned rats by 30% and 60%, respectively. 5- 
HTlnonAB(3C receptors, which were most abundant in the striatum 
of intact rats, were increased by 35% in rostral striatum of 
n6-OHDA-lesioned rats (Radja et al. 1993).
In the caudal striatum, as in rostral striatum, 5-HT1B 
and 5-HTlnonAB|3C receptors were increased by 30 to 35%, while
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5-HTaA receptors were not altered in numbers in n6-OHDA- 
lesioned rats. Because numbers of 5-HTJA receptors and 
numbers of 5-HT fibers are increased in rostral striatum of 
n6-0HDA rats, it was suggested that 5-HT fiber proliferation 
accounted for the change in 5-HTax receptor number (Radja et 
al., 1993).
There was no change in the number of 5-HT1A receptors 
in lateral septum, CA1 area, dentate gyrus and dorsal raphe 
of nfi-OHDA-lesioned rats. Similarly, there was no change in 
the number of 5-HTaA receptors in claustrum and nucleus 
accumbens of n-6-OHDA-lesioned rats. It was suggested that 
the cumulative upregulation of assorted 5-HT receptor 
subtypes would effectively enhance actions of synaptic 5-HT, 
even if the synaptic content of 5-HT was the same as in 
intact rats (Radja et al., 1993).
L. Tardive Dyskinesia (TD)
TD is a syndrome of involuntary, repetitive and 
purposeless hyperkinetic abnormal movements that occur 
during or after chronic neuroleptic treatment. Orofacial 
regions and sometimes the limbs and trunk are most commonly 
involved (Waddington, 1990,* Jeste and Caligiuri, 1993).
TD was first described by Schonecker (1957), five years 
after the introduction of the neuroleptic chlorpromazine as 
a treatment of psychosis. The term "tardive dyskinesia" was 
first used by Faurbye et al. in 1964 to describe this late- 
developing movement disorder (Faurbye et al., 1964). Long-
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term use of neuroleptics is the major risk factor for TD 
(Jeste and Caligiuri, 1993).
The reported prevalence of TD varies from 0.5 to 100%. 
This wide range may be due to the differences in risk 
factors, treatment characteristics and diagnostic criteria. 
Conservatively, it is usually agreed that the prevalence of 
TD is between 15 to 20%. In high risk patients, such as the 
elderly, the prevalence is as much as 70% {Casey, 1987).
M. Risk Factors for TD
1. Age and Gender
Age is the primary risk factor for TD, with there being 
a positive correlation between the prevalence and severity 
of TD with age (Smith and Baldessarini, 1980; Jeste and 
Wyatt, 1982b). Age-related degeneration of the 
nigrostriatal DA system may be one underlying basis of this 
phenomenon (Jeste and Caligiuri, 1993). A higher incidence 
with greater severity of TD occurs in females (Casey, 1987) .
2. Psychiatric diagnosis
Neuroleptic-treated schizophrenic patients are less 
likely to develop TD than neuroleptic-treated mood disorder 
patients (Casey and Keepers, 1988; Mukherjee et al., 1986).
3. Organic brain damage
Since TD is the consequence of treatment of patients 
with mental disorders, it is possible that CNS damage may be 
a risk factor for TD (Yassa et al., 1984). There is some 
disagreement with this view (Gold et al., 1991). In future
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studies it would be valuable to assess the relationship 
between TD and brain damage.
4. Other factors
There is reportedly a higher incidence of TD in people 
that smoke or have diabetes. Asians have the lowest 
incidence of TD, indicating that ethnicity or genetic 
differences may represent risk factors for TD (Jeste and 
Caligiuri, 1993; Yassa et al., 1987).
N. Tardive Dyskinesia and Central DA Neurons
Up until recently the most widely-accepted hypothesis 
on the origin of TD was that TD was related-to development 
of DA receptor supersensitivity. This was based mainly on 
the knowledge that movements disorders are a consequence of 
DA receptor block in the nigrostrial system. It is 
extremely difficult to conduct postmortem studies on TD 
patients, since this is a neuroleptic-induced disorder and 
the therapy is often sufficiently variable so that it is 
difficult to reasonably group patients into subsets. Also, 
residual neuroleptics in these patients would still exert a 
block of brain DA receptors. Therefore, most evidence on 
the pathophysiology of TD are derived from animal models 
(Casey, 1987).
In studies on intact and/or n6-0HDA-lesioned rats it 
has been found that oral activity is induced by DA Dt 
agonists (SKF 38393 and A77636) and DA Da antagonists 
(sulpiride, spiperone and haloperidol). Therefore, it
appears that an imbalance of D1/D2 receptor activity plays a 
prominent role in the induction of oral activity 
(Rosengarten et al., 1983; Gong et al., 1992; Huang and* 
Kostrzewa, 1994b). In studies on rats treated long-term 
with neuroleptics, an increase in the Bmax and Kd for DA 
receptors has been reported {Chiu et al., 1981; Rupniak et 
al., 1984). These associated behavioral and biochemical 
indices are supportive of the hypothesis that an overactive 
DA system may contribute to the pathophysiology of TD 
(Klawans, 1973; Chiu et al., 1981; Rupniak et al., 1984; 
Jeste and Caligiuri, 1993).
In other subsequent studies, there have been findings 
that conflict with those just described. Waddington et al. 
(1983), using direct measurements on postmortem brain from 
humans with TD, found that there was a dissociation between 
behavioral and DA receptor changes. Blin et al. (1989), 
using positron emission tomography on brains of humans with 
TD, also found a discrepancy between oral dyskinesias and 
changes in DA receptors. Recently, attention has been 
focused on a multi-neurotransmitter theory of TD, in which 
there is a seeming imbalance between regulation by different 
kinds of neurons (Casey, 1987; Waddington, 1990; Jeste and 
Caligiuri, 1993} .
O, Regulation of Oral Activity in Rats by Multiple 
Neurochemical Systems
It is well-established that DA neuronal systems have an
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integral role in regulating oral activity in rats 
(Rosengarten et al., 1983; Gong et al., 1992; Kostrzewa and 
Gong, 1991; Kostrzewa and Hamdi, 1991; Huang and Kostrzewa, 
1994a). Serotoninergic (Stewart et al., 1989; Gong et al., 
1992; Kostrzewa et al., 1992), cholinergic (Rupniak et al., 
1983, 1985a; Salamone et al., 1990), GABAergic (Gunne et 
al., 1984; Morelli et al., 1985; Lloyd et al., 1985) and 
peptidergic (Liminga, 1993) neurons are also involved in 
regulating oral activity.
Acute treatment with the cholinergic agonist 
pilocarpine significantly increases oral activity in rats. 
This effect is produced when pilocarpine is administered 
directly into the ventrolateral striatum via a cannula 
implant. Also, when pilocarpine or the cholinesterase 
inhibitor physostigmine is administered in drinking water 
for three weeks, there is an increased incidence of oral 
activity (Rupniak et al., 1985b). The effect of pilocarpine 
and physostigmine in this last study was attenuated by the 
muscarinic receptor antagonist, scopolamine (Salamone et 
al., 1990). The acute treatment of chronic haloperidol- 
treated rats with pilocarpine or physostigmine results in an 
increased number of oral movements in rats (Rupniak, 1983). 
It is yet to be determined, however, whether cholinergic- 
induced oral activity represents an oral dystonia or an oral 
dyskinesia.
It is possible that GABA agonists have a therapeutic
effect on dyskinesia, since GABA agonists interact with DA 
systems to alter behavioral responses (stereotyped and 
dyskinetic movements) induced by lesions or DA agonists 
(Gunne et al., 1984; Morelli et al., 1985). It was reported 
that the GABA agonists muscimol and progabide have 
beneficial effects on TD patients (Lloyd et al., 1985; 
Morelli et al., 1985; Tamminga et al., 1979). In animal 
studies, a microinfusion of the GABA antagonist bicuculline 
and GABA-depleting agent isoniazid bilaterally in the 
substantia nigra greatly increased oral activity of rats 
(Gunne et al., 1988). GABA agonists attenuated oral 
activities of cats, monkeys and rats (Lloyd et al., 1985; 
Mithani et al., 1987). These findings suggest that an 
impaired GABA system may be involved in abnormal oral 
activities (Mithani et al., 1987).
Central (intranigral) or peripheral administration of . 
receptor agonists [1,3-di-o-tolylguanidine (DTG) and {+)- 
pentazocine] or the . receptor antagonist naloxone resulted 
in increased oral activity in rats. This may be related to 
a release of DA in the striatum (Patrick et al., 1993; 
Cancela et al., 1988). It is also known that the 
intranigral infusion of the neurokinin NK1 agonist substance 
P and NKj agonist neurokinin A produce dose-related 
increases in purposeless oral activity in rats. These 
findings are compatible with the view that central 
neuropeptides are involved in the regulation of oral
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activity (Liminga, 1993).
Extensive studies have been conducted to explore the 
effects of DA 5-HT and cholinergic systems in regulating 
oral activity in neonatal 6-OHDA-lesioned rats. In n6-OHDA- 
lesioned rats, there were enhanced oral activity responses 
to the DA Dt agonist SKF 38393, the 5-HTa agonist m- 
chlorophenylpiperazine (m-CPP) and cholinergic agonist 
pilocarpine (Kostrzewa and Gong, 1991; Gong and Kostrzewa, 
1992; Gong et al., 1992; Kostrzewa and Neely, 1993). These 
findings indicate that there is co-sensitization of DA, 5-HT 
and cholinergic systems in n6-OHDA-lesioned rats (Kostrzewa, 
1995). Of the several 5-HT agonists that were tested in 
these rats, only the 5-HTaAiac agonist m-CPP induced oral 
activity. The 5-HT1A agonist (±) -8-
hydroxydipropylaminotetralin (8-OH-DPAT) and 5-HT1B agonist
7-trifluoromethyl-4(4-ethyl-l-piperazinyl)-pyrrolo[l,2r 
alquinoxaline] (CGS 12066B) did not increase the incidence 
of oral activity. Furthermore, the enhanced oral response 
to m-CPP was attenuated by the 5-HTaA)JC receptor antagonist 
mianserin, but not by the 5-HT1AtlB antagonist pindolol, 5- 
HTaA antagonist ketanserin or 5-HTa antagonist MDL-72222 (3- 
tropanyl-3,5-dichlorobenzoate). These findings indicate 
that m-CPP-induced oral activity is mediated by 5-HTac 
receptors and not the other 5-HT receptor subtypes (Gong et 
al., 1992) .
In other studies on n6-0HDA-lesioned rats it was
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reported that the DA Dt receptor antagonist SCH 23390 did 
not attenuate m-CPP-induced oral activity, but that the 5-HT 
receptor antagonist mianserin attenuated oral activity 
induced by the DA agonist SKF 38393. This indicates that 
DA agonist-induced oral activity is mediated by 5-HTac 
receptors (Gong et al., 1992). In a later study it was 
found that the muscarinic receptor antagonist scopolamine 
effectively blocked the oral activity response to both SKF 
38393 and m-CPP, but that SCH 23390 and mianserin did not 
block the response to pilocarpine. This finding indicates 
that oral activity induced by DA and 5-HT systems are 
mediated by cholinergic systems. Therefore, these series of 
studies indicate that DA neurons are acting via 5-HT neurons 
which are acting via cholinergic neurons (Kostrzewa and 
Neely, 1993) .
P. Rationale
The introduction of neuroleptics into clinical practice 
in 1952 was a milestone in the treatment of psychiatric 
disorders. However, the beneficial effects of these drugs 
were soon found to be counterbalanced by the appearance of 
the serious syndrome known as tardive dyskinesia (TD). The 
underlying basis of this adverse effect is still not known. 
An earlier theory on the origin of TD was assumed to be 
related to the development of DA receptor supersensitivity 
(Klawans and Hitri, 1978; Chiu et al., 1981). Today the 
multi-neurotransmitter theory, based on the involvement of
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many neurochemical systems (Waddington* 1990; Caligiuri* 
1993)* seems to be more in vogue. Waddington (1990) has 
critically reviewed the literature. Nonetheless* there*has 
been a steady increase in the incidence of TD by about 1% 
per year during the past 20 years (Casey, 1987; Jeste and 
Caligiuri, 1993) .
Animal models that mimic the pathophysiology of human 
TD are useful for studying putative mechanisms associated 
with spontaneous oral activity and in studying potentially 
useful drugs for TD. Non-human primates (Gunne et al.,
1984; Kovacic and Domino, 1984) and rodent models of TD 
(Ellison and See, 1989; Waddington, 1990} have been used.
The most common animal model is chronic neuroleptic (usually 
haloperidol)-treated rats.
There is still no single animal model which reproduces 
the exact phenomenology of TD, particularly the 
characteristic oral movement found in TD patients. This may 
be related to the fact that neuroleptics are usually 
administered to psychotics, who are known to have an altered 
disturbance in the CNS. In contrast, the animals receiving 
the neuroleptic are normal healthy rodents (Waddington,
1990).
In rats in which the neostriatal DA innervation has 
been destroyed early in postnatal ontogeny by 6-OHDA, the 
incidence of oral activity is greatly increased by DA 
agonists (Kostrzewa and Hamdi* 1991; Kostrzewa and Gong*
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1991) and 5-HT agonists (Gong et al., 1992). Rats lesioned 
neonatally with 6-OHDA have been proposed as a better model 
for TD (Gong et al., 1992; Huang and Kostrzewa, 1994b).
In order to test this hypothesis the following study 
was performed. Haloperidol was added to the drinking water 
of intact and neonatal 6-OHDA-lesioned rats for nearly 1 
year, while spontaneous and agonist-induced oral activity 
was observed at one or two week intervals. The objective 
was to determine whether:
a. persistent oral dyskinesias might be induced in 
haloperidol-treated 6-OHDA-lesioned rats,
b. mRNA levels of DA D, and 5-HTJC receptors might be 
altered to different extents in intact and 6-0HDA- 
lesioned haloperidol-treated rats,
c. DA Dj receptor number might be altered by 
haloperidol treatment of intact and 6-OHDA- 
lesioned rats and
d. receptor-specific compounds might attenuate 
spontaneous oral activity in treated rats.
This study was expected to lead to a better 
understanding of the pathophysiology of TD, particularly of 
the roles of DA and other neurotransmitter systems in 
regulating oral activity. More significantly, there was the 
potential for inducing long-lived spontaneous oral 
dyskinetic activity'in rats, so that putative drugs for TD 
could be reasonably tested for their ability to attenuate
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TD.
Chapter 2 
Materials and Methods
A. Animal Treatment
1. Animal
Time-pregnant Sprague-Dawley albino rats were purchased 
from Charles River Laboratories (Research Triangle, NC) 
approximately 1 week before delivery and housed singly in 
clear Perspex cages in a room with constant temperature 
(21±1<,C) and 12 h light-dark cycle (lights on at 07:00) . 
Animals had free access to food and water. The date of 
birth was considered as postnatal day 0. The time of birth 
was recorded within 12 hr. Litters were reassigned at 
birth, so that each reconstituted litter consisted of about 
equal number of pups from 10 different litters, for a 
maximum of 10 pups per litter.
2. 6-OHDA Treatment
At 3 days after birth all rat pups were pretreated with 
desipramine hydrochloride (20 mg/kg i.p., base form; Sigma 
Chemical Co., St. Louis, MO, USA), 1 hr before bilateral 
intracerebroventricular (icv) administration of 6-OHDA. The 
desipramine was intended to block NE transporters and 
protect NE-containing neurons from 6-OHDA toxicity, thereby 
increasing the selectivity of 6-OHDA for DA-containing 
neurons. 6-OHDA HBr (100 fig, salt form, on each side; 
Research Biochemicals Inc., Natick, MA, USA) was delivered
35
36
via a microliter syringe equipped with a 26-gauge needle 
having a polyethylene sleeve up to 2 mm from the tip of the 
needle. The injection was positioned 1.5 mm anterior to 
lambda and 2 mm lateral to the sagittal plane. The needle 
was left in place for about 30 seconds after 5 pLl of 6-OHDA 
HBr solutions or 0.1% saline-ascorbic acid vehicle was 
injected into the lateral ventricle. This procedure has 
been described in detail {Kostrzewa and Gong, 1991). Rats 
were weaned at 28 days and group housed in wire cages. Only 
males were used in this study.
3. Haloperidol Treatment
Starting 2 months after birth about half the rats in 
the 6-OHDA and vehicle groups received haloperidol (1.5 
mg/kg/day) via drinking water, for 2 consecutive days a week 
for 4 weeks. Starting in the fifth week haloperidol was 
administered on a continuous schedule (1.5 mg/kg/day) for 10 
months. Thus, the study consisted of four groups: (1) non- 
lesioned rats with tap water as drinking water, (2) non- 
lesioned rats with haloperidol in drinking water, {3} 6- 
OHDA-lesioned rats with tap water as drinking water, and {4}
6-OHDA-lesioned rats with haloperidol in drinking water.
The dose of haloperidol in this study reputedly produces 
plasma levels of haloperidol that correspond to that of 
people treated long-term with haloperidol (Tamminga et al., 
1990). Rats were weighed once a week to adjust the dose of 
haloperidol.
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4. Observation of Oral Activity
»
Spontaneous oral activity was observed one week before 
instituting haloperidol treatment, then every 1 or 2 weeks 
until the end of the study. A variety of receptor-specific 
drugs for different neurotransmitter systems were tested for 
their effect on oral activity, during and after the phase of 
haloperidol treatment. These included drugs selective for 
DA, serotonin, cholinergic, GABAergic and glutamatergic 
systems. Also, oral activity dose-effect curves for the DA 
Di agonist SKF38393 and 5-HT, agonist m-CPP were constructed 
for all groups of rats at 12, 36 and 38 weeks after 
haloperidol treatment. Haloperidol was withdrawn after 11 
months of treatment. Eight or nine days after withdrawing 
haloperidol all rats were killed, except for 9 of the 6- 
OHDA-lesioned group that had received haloperidol for the 
past ll months. Oral activity in these rats continued to be 
observed for the following 8 months.
Oral activity determinations were performed in a well- 
ventilated and well-lighted room. Rats were placed 
individually in clear plastic cages (48 X 26 X 36 cm) with 
steel grid floors and acclimated for at least 30 min. 
Agonists or saline vehicle were administered ip to each rat 
(1 mg/kg) 10 min before observation. Antagonists or vehicle 
were administered ip 1 hour before observation. All 
observation sessions were conducted with 9 rats per group 
except when deaths reduced the pool size in 6-OHDA-lesioned
haloperidol-withdrawn rats. Numbers of oral movements were 
counted in each rat by an experienced observer, for l min 
every 10 min during a 60 min session. Oral activity 
represents spontaneous chewing {vacuous chewing) which is 
not directed onto any physical material (Rupniak et al., 
1983; Waddington, 1990). No distinction was made between 
lateral and vertical jaw movements. Directed oral activity 
and food chewing sequences were not counted (Kostrzewa and 
Gong, 1991; Huang and Kostrzewa, 1994a,b).
B. Neurochemical Analysis of Striatum
Eight or nine days after the withdrawal of haloperidol 
rats were killed by decapitation. Each brain was rapidly 
removed and the striata were dissected free, frozen on dry 
ice and stored at -70°C until the time of analysis.
Concentrations of DA, 5-HT and their metabolites in rat 
striatum were determined by liquid chromatography with 
electrochemical detection (LCEC). Each striatum was 
sonicated in 1 ml of 0.10 M trichloroacetic acid containing
0.20 mg/ml of cysteine as a stabilizing agent. 5- 
hydroxyindole carboxylic acid was used as internal standard. 
Homogenates were centrifuged at 12,000 x g for 5 min and 30 
Hi of each supernate was injected onto an Econosphere Cl8 
analytical column (5 micron, 4.6 x 150 mm), having a mobile 
phase of 0.10 M monochloroacetic acid, 1 mM EDTA, 220 mg/1 
of Na octanesulfonic acid, 8% acetonitrile, pH 2.6, with a 
flow rate of 1.3 ml/min and temperature of 40 °C (Gong et
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al., 1992). A Hewlett-Packard HP1000 chromatography data 
system was used to calculate peak heights and to determine 
concentrations of DA, DOPAC, homovanillic acid (HVA), 5-HT, 
5-hydroxyindoleacetic acid (5-HIAA) and noreprenophine (NE).
C. Assessment o£ Striatal D, Receptor Binding Parameters
A modification of the procedure of Dewar et al. (1989, 
1990) was used to assess DA D, receptors in the striatum. 
Rostral striata were homogenized with a Teflon on glass 
mortar and pestle in 1:100 ice-cold 50 mM Tris buffer (pH 
7.4). This gentle homogenizing procedure was used to avoid 
damage to receptors during this tissue preparation step 
(Norman et al., 1989). Homogenates were then centrifuged at 
35,100 x g for 10 min at 4°C using a Beckman J2-21M 
centrifuge and JA-20.1 rotor. The supernatants were 
discarded and the pellets were washed 4 times in the Tris 
buffer by repeated pipettings, followed by centrifugation. 
Final pellets were resuspended in 200 volumes of buffer.
Saturation curves were obtained in the following way. 
Aliquots of homogenate (2 mg membrane in 400 fil) were added 
to a series of incubation tubes with 10 different 
concentrations (93-8245 pM) of the DA Da receptor antagonist 
[JH]raclopride (specific activity: 82.4 Ci/mmol; Dupont).
The incubate consisted of Tris buffer (pH 7.4) containing 
120 mM NaCl, 5 mM KC1 and 40 nM ketanserin (final cones.). 
Samples were incubated in a final volume of 2.5 ml at 25 “C 
for 60 min. The incubation was terminated by rapidly
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filtering each sample under partial vacuum on Whatman GF/F 
glass filters using a Millipore filtration unit. Filters 
were washed 3 time each with 5 ml ice-cold Tris-salt 
solution, then placed into scintillation counting vials. 
After drying overnight, 9 ml of scintillation solution was 
added to each vial. Tritium activity was determined in a 
Beckman L5 9800 liquid scintillation spectrometer.
A GraphPad program (GraphPad Software Inc., San Diego, 
CA) was used to construct the binding curves and calculate 
receptor binding parameters, and Kd, by fitting the data 
to a double rectangular hyperbola equation [Y = A*X/(B+X) + 
C*X/(D+X) + E*X]. Factor B in this equation was set as a 
constant of zero since there was only one binding site for 
Da receptors (Fig. l, sequential F test, P>0.05) (Dewar et 
al., 1989, 1990).
D. Determination of mRNA levels for DJL, D„ and 5-HTac 
receptors in the striatum
1. Messenger RNA Extraction and Purification
Total RNA was isolated and purified according to the 
Ultraspec™-ll RNA Isolation System (Biotecx Laboratories, 
Inc., Houston, TX). The rostral striatum of each rat was 
homogenized in 1 ml of Ultraspec™ RNA reagent with a Tekmar 
Tissumizer, setting of 5 for 25 sec. Homogenates were 
transferred to 1.5 ml polypropylene microcentrifuge tubes 
and kept at 4°C for 5 min to allow dissociation of 
nucleoprotein complexes. Then, 0.2 ml of chloroform was
added to each isolation tube, followed by vigorous shaking 
for IS seconds. After 5 min on ice, homogenates were 
centrifuged at 12,000 g for 15 min and the upper aqueous 
phase which contained RNA was carefully transferred to a 
fresh tube -- taking care not to disturb the interphase and 
the lower organic phase. Each tube was vortexed for 30 
seconds after the addition of 0.5 volumes of isopropanol and
0.05 volumes of RNA Tack™ Resin. Following a 1 min 
centrifuge step with a table-top minicentrifuge, 
supernatants were discarded and the pellets were washed with 
2 x 1  ml of 75% ethanol by vortexing for 30 seconds and 
spinning for l min. The supernatants were discarded. All 
tubes were dried for 5 min in a vacuum centrifuge (VirTis 
Co., Gardiner, NY) to remove traces of ethanol. Pellets 
containing RNA were eluted with diethyl pyrocarbonate 
(DEPC)-treated water by vortexing for 30 seconds and then 
spinning for 1 min. Supernatants containing RNA were 
transferred to 0.6 ml polypropylene tubes and stored at 
-70°C until used. Ten pi of aliquot RNA solution of each 
sample was transferred into 490 pi of DEPC-treated water and 
the optical densities of the samples at 260 nM and 280 nM 
were obtained, to determine the concentration and purity of 
the final RNA solutions.
2, Polymerase Chain Reaction (PCR)
mRNA determinations were performed with Perkin Elmer 
GeneAmp RNA PCR Kit (Roche Molecular Systems, Inc.,
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Branchburg, NJ). One microgram of total RNA from each 
sample was transcribed into single-stranded cDNA, using MuLV 
reverse transcriptase and random hexamers and incubating 
(42°C for IS min, 99°C and 5°C for 5 min each) in a Perkin 
Elmer GeneAmp PCR system 9600 (Perkin Elmer, Roche Molecular 
systems, Inc., Branchburg, NJ).
Two oligonucleotides (24-mer) flanking the alternative 
spliced exon 6 of Da receptor cDNA were used for 
amplification of the mRNA levels of two isoforms of D, 
receptor, Datl and Das. The sequences of these two primers 
(Martres et al., 1992; Della Vedova et al., 1992) are: 
primer 1: 5'-TTCAGAGCCAACCTGAAGACACCA-3' (nucleotides 694- 
717); primer 2: 5'GCTTTCTGCGGCTCATCGTCTTAA-3' (nucleotides 
1067-1090) . The amplified fragment of Dat and Das receptors 
were 397-bp and 310-bp respectively.
The levels of S-actin mRNA were also determined and 
this served as the internal standard. Two primers (Martres 
et al., 1992) for fi-actin mRNA detection were 5'- 
GATGGTGGGTATGGGTCAGAAGGA-3' (nucleotides 129-152) and 5'- 
GCTCATTGCCGATAGTGATGACCT-3' (nucleotides 737-760). The 5- 
HTac receptor primers were 5'-ACACCGAGGAGGAACTGGCTAATAT-3' 
and 5'-CTGGTAAACAGAACTGCCTCCGACTATC-3' which define a 601- 
base-long DNA fragment. Amplification was carried out for 
35 cycles using a DNA thermal cycler (Perkin Elmer Cetus) at 
the following condition: 95°C for 45 seconds, 58°C for 30 
seconds and 72°C for 45 seconds. The final products after
amplification were fractionated on 2% Metaphor high- 
resolution agarose gel and stained with ethidium bromide.
Two bands of 397-bp and 310-bp for D3L and Dia receptors, a 
band of 601-bp for 5-HTac receptors and a 632-bp band for fi- 
actin were viewed and photographed with Polaroid positive 
film (type 665) under an ultraviolet (UV) light source. The 
optical densities and areas of each band were analyzed by a 
Bio Image Analysis System (Millipore Corporation Imaging 
Systems, Ann Arbor, MI).
E. Data Analysis
1. Oral Activity:
Oral activity was expressed as the mean number of oral 
movements in 6 min of a 60 min observation session ± S.E.M. 
Statistically significant differences in oral activity 
between groups was determined by one-way ANOVA, followed by 
the post-ANOVA Newman-Keuls test. In the case where 
receptor-specific drugs were tested for their ability to 
attenuate oral activities, the Student paired t-test was 
used to determine significant differences within a group of 
animals before and after administration of the drug.
2. Monoamine Determinations:
The mean tissue concentration of each monoamine and 
metabolite (nmol/gram ± S.E.M.) was determined for all 
groups of rats. Differences between the groups for each of 
these substances were determined by one-way ANOVA and a 
post-ANOVA Newman-Keuls test.
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3. D3 Receptor Binding Parameters:
The double rectangular hyperbola equation of GraphPad, 
using total membrane binding (DPM/fmol protein) for each 
incubate concentration of [JH]raclopride (93-8245pM), was 
used to construct specific- and nonspecific-binding curves 
and to calculate values for and Kd. It was determined 
that there was only one binding site for [3H] raclopride, in 
agreement with Dewar et al. {1989, 1990). Differences in 
and Kd between the groups were tested by one-way ANOVA, 
followed by the post-ANOVA Newman-Kwuls test.
4, D3 and 5-HT3C Receptor mRNA levels.*
The relative levels of mRNA for each receptor were 
expressed as a product of optical density and area of the 
individual gel bands, following adjustment for internal 
standard variations [i.e., dividing by levels of fi-actin 
mRNA (optical density x area)]. The mean (± S.E.M.) content 
of the mRNA levels of each group was then determined, and 
these were compared among the different groups by one-way 
ANOVA and the post-ANOVA Newman-Keuls test.
A P value equal to or less than 0.05 was considered to 
be statistically significant in all of the statistical 
analyses.
Chapter 3 
Results
A. Before Haloperidol Withdrawal
l. Spontaneous Oral Activity
In intact rats receiving tap water, the incidence of 
spontaneous oral activity was'low for the entire duration of 
the experiment, remaining at less than 5 oral movements per 
session (Fig.2; Fig.3, 1st, 5th and 9th bars). The 
spontaneous oral activity of n6-0HDA-lesioned rats that were 
kept on tap water was slightly but not significantly higher 
than that in the intact rat and remained stable for the 
entire experiment duration (Fig. 2; Fig. 3, 2nd, 6th and 
10th bars).
Starting in the 15th week of haloperidol treatment, 
there was a significantly higher incidence of oral activity 
in all haloperidol-treated rats (Fig.2 and Fig.3, P<0.01). 
The high level of spontaneous oral activity remained stable 
for the entire duration of haloperidol treatment (Fig.2).
In intact rats oral activity ranged from 14.4 to 20.4 oral 
movements per session during the 11-month period of 
haloperidol treatment (observations at 1- or 2-week 
intervals). In the latest session there were approximately 
18 oral movements, a 4-fold increase vs. intact rats on tap 
water (Fig.2 and Fig.3, 1st, 3rd, 7th and 11th bars,
P<0.01). A much greater effect was produced by haloperidol 
administration to neonatal 6-OHDA-lesioned rats. In these
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rats spontaneous oral activity ranged from 27.6 to 41.6 oral 
movements per sessions during the 11-month period of 
haloperidol treatment. In the latest session there were 36 
oral movements, double that of intact rats which received 
haloperidol {Fig.3, 7th and 8th, 11th and 12th bars PcO.Ol).
2. Super sensitization of DA and 5-HT systems
a. DA system
Dose-response curves for SKF 38393-induced oral 
activity were constructed at 12 weeks and 36 weeks after the 
administration of haloperidol (Fig.4 and Fig.S). As 
expected, the 0.3 and 1.0 mg/kg doses of SKF 38393 
significantly (P<0.01) increased oral activity in n6-OHDA- 
lesioned rats during the 12th and 36th weeks of haloperidol 
treatment. The oral activity of n6-OHDA-lesioned rats 
receiving haloperidol was also increased at the above 2 time 
points with the same SKF 38393 doses. This indicates that DA 
DL-mediated oral responses were enhanced in both* n6-OHDA- 
lesioned and n6-OHDA-lesioned rats receiving haloperidol 
treatment.
b. 5-HT system
The sensitivity of 5-HTac-mediated oral responses of 
rats was also tested. It recognized that m-CPP-induced oral 
activity is mediated by 5-HTac receptors (Gong et al, 1992). 
The dose-response curves for m-CPP-induced oral activity 
were performed at 12th and 38th week of haloperidol 
treatment. m-CPP produced bell-shaped dose-response curves
47
in n6-OHDA-lesioned rats, n6-0HDA-lesioned rats receiving 
haloperidol and intact rats receiving haloperidol, the 
optimal dose was 1.0 mg/kg (i.p.). Oral activities o£ these 
three groups of rats were significantly increased by m-CPP 
(Fig.6 and Fig.7}. These results demonstrate that there is 
enhanced 5-HTac-mediated oral activity in n6-OHDA rats and 
in both groups of haloperidol-treated rats.
3. Effects of assorted receptor agonists and antagonists on 
oral activity
a. DA Dt receptor antagonist
At a 1.0 mg/kg dose, the DA Da receptor antagonist SCH 
23390 had no effect on the oral activity of both intact and 
n6-0HDA-lesioned rats receiving tap water. However, the 
same SCH 23390 dose produced a significant reduction of oral 
activity in both groups of rats that received haloperidol 
(Fig. 9, P<0.05 for intact rats receiving haloperidol,
PcO.Ol for n6-OHDA-lesioned rats receiving haloperidol).
b. 5-HTac receptor antagonist
m-CPP and SKF 38393 produced significantly increased 
oral activity in n6-0HDA-lesioned rats and both groups of 
rats receiving haloperidol (Fig.9, 6th, 7th, 8th and 10th, 
11th, 12th bars vs, 2nd, 3rd and 4th bars respectively, 
PcO.Ol). The enhancement of oral activity induced by these 
two agonists was attenuated by mianserin (1.0 mg/kg). This 
finding indicates that both SKF 38393 and m-CPP-induced 
oral activity is mediated by a neural circuit with 5-HT
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receptors.
c. GABA receptor agonist and antagonist
Muscimol, a GABAa receptor agonist, at the dose of 3.0 
mg/kg, significantly attenuated the number of oral movements 
in n6-OHDA-lesioned rats receiving haloperidol (Fig.10, 
P<0.05). This same dose of muscimol had no effect on oral 
activity of intact rats receiving tap water or haloperidol; 
and no effect on oral activity of n6-0HDA-lesioned rats 
receiving tap water (Fig.10). The GABA receptor antagonist 
bicuculline (1.0 mg/kg) did not influence oral activity in 
any of the groups (Fig.11).
d. Cholinergic receptor antagonist
The effect of the muscarinic receptor antagonist 
scopolamine on oral activity of all rats was also tested 
(Fig.12). Analogous to SCH 23390, scopolamine (0.1 mg/kg) 
had no effect on oral activity of intact and n6-0HDA- 
lesioned rats receiving tap water. However, oral activity of 
intact and n6-OHDA-lesioned rats receiving haloperidol was 
significantly attenuated (Fig.12, P<0.05 and <0.01 
respectively).
B. After Haloperidol Withdrawal
1. Spontaneous oral activity
In order to determine whether the haloperidol-induced 
increased in spontaneous oral activity would persist in n6- 
OHDA-lesioned rats, nine of the n6-OHDA-lesioned rats 
receiving haloperidol continued to be observed after the
withdrawal of haloperidol. These rats were observed 
periodically (once a week) for 8 months. The high incidence 
of oral activity of these rats remained stable (range of 
28.5 to 38.5 oral movements per session) for the duration of 
the experiment--8 months after the withdrawal of haloperidol 
(Fig.13). This finding indicates that chronic haloperidol 
treatment produces a long-lived increase in spontaneous oral 
activity of n6-0HDA-lesioned rats. In order to assess the 
long-term effects of haloperidol on DA and 5-HTac receptors, 
it was necessary to take brain tissue within several days 
after the cessation of haloperidol. For that reason, and 
based on the previously reported rapid decay of spontaneous 
oral activity in intact rats after cessation of haloperidol 
treatment (Tamminga et al., 1990; Mithani et al., 1987), it 
was not able to observe this group after haloperidol 
withdrawal.
2. .Effects of assorted receptor agonists and antagonists on 
spontaneous oral activity
In order to determine the possible neuralmechanisms 
underlying the regulation of oral activity, the effect of a 
series of receptor-specific drugs was tested in the n6-OHDA- 
lesioned rats during the haloperidol-withdrawal period,
a. DA receptor antagonists
SCH 23390 (1,0 mg/kg) had no effect on spontaneous oral 
activity of n6-OHDA-lesioned rats after haloperidol 
withdrawal. The DA Da receptor antagonists spiperone (0.08
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mg/kg, i.p.) and metoclopramine (5.0 mg/kg, i.p.) also had 
no effect on oral activity of these rats (Fig.14}.
b. 5-HT receptor antagonists
Ketanserin (5.0 mg/kg), pindolol (3.0 mg/kg) and 
metoclopramine (5.0 mg/kg), respective 5-HTJA/ac, 5-HTlA/1B and 
5-HTj receptor antagonists, had no effect on oral activity 
of n6-OHDA-lesioned rats after haloperidol withdrawal 
(Fig. 15) . These results suggest that 5-HTlA/lB, 5-HTaA and 5- 
HTj receptors are not involved in regulating oral activity.
c. Drugs acting on other neuronal receptors 
Drug acting on GABA receptors
Muscimol (3.0 mg/kg, i.p.), a GABA receptor agonist, 
significantly attenuated oral activity in nG-OHDA-lesioned 
rats after haloperidol withdrawal (P<0.01, Fig.IS). 
Spontaneous oral activity of these rats was reduced from 
28.1 ± 4.4 to 16.0 ± 3.9 movements per session after 
muscimol. These results support the view that GABA is one 
of the neuronal systems involved in the regulation of oral 
activity (Gunne et al., 1984; Morelli et al., 1985).
Drug acting on cholinergic receptors
Before withdrawing haloperidol, the muscarinic receptor 
antagonist scopolamine (0.1 mg/kg, i.p.) significantly 
attenuated spontaneous oral activity in both intact and n6- 
OHDA-lesioned rats receiving haloperidol treatment (Fig.12). 
However, after the withdrawal of haloperidol, the high 
incidence of oral activity in n6-OHDA-lesioned rats was not
attenuated by scopolamine. The spontaneous oral activity of 
these rats was 30.5 ± 6.6 and 23.5 ± 3.0 movements per 
session respectively before and after scopolamine (P>0.05, 
Fig. 16). The different effects of SCH 23390 and 
scopolamine on spontaneous oral activity before and after 
haloperidol withdrawal suggest that oral activity is 
regulated differently in these two phases. The failure of 
scopolamine to inhibit oral activity after haloperidol 
withdrawal indicates that the characteristics of oral 
activity are analogous to the oral activity in TD patients 
since it is usually agreed that scopolamine•alleviate the 
early emergence of oral dystonia whereas cholinergic drug 
improve the symptoms of tardive dyskinesia (Rupniak et al, 
1984; Waddington, 1990).
Drugs acting on adrenergic receptors
Phenoxybenzamine (10.0 mg/kg) and phentolamine (2.0 
mg/kg), two a-adrenoceptor antagonists, had no effect on 
spontaneous oral activity of n6-OHDA-lesioned rats after 
haloperidol withdrawal. Similarly, the fi-adrenoceptor 
antagonist propranolol (20.0 mg/kg) had no influence on 
spontaneous oral activity of these rats (table 1). This 
implies that adrenergic systems do not have a prominent role 
in regulating oral activity of these rats.
Drugs acting on histamine and adenosine receptors
Cyproheptadine (0.3 mg/kg) and ranitidine (5.0 kg/mg), 
respective histaminergic and Ha receptor antagonists, and
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theophylline (20 mg/kg), an adenosine receptor antagonist, 
failed to attenuate spontaneous oral activity of the n6- 
OHDA-lesioned rats after haloperidol withdrawal (table l') . 
Drugs acting on NMDA. and opioid receptors
Ketamine (10.0 mg/kg), an NMDA receptor antagonist, and 
naloxone (1.5 mg/kg and 5.0 mg/kg), an opioid mu receptor 
antagonist, did not significantly alter oral activity in the 
n6-0HDA-lesioned rats after haloperidol withdrawal. At a 
dose of 0.3 mg/kg, MK-801, an NMDA receptor antagonist, 
significantly reduced the number of oral movement in these 
rats (table l). However, treatment with MK-801 also caused 
prominent salivation and sedation in these rats. All rats 
were virtually immobile after MK 801 treatment. Therefore, 
the reduction of oral activity by MK-801 in these rats may 
be more reflective of general central nervous system 
depression.
C. Changes of mRNA Levels of DA Da and 5-HTac Receptors 
To correlate the functional changes with molecular 
mechanisms, the relative messenger RNA levels of DA DaL and 
Daa receptors, two isoforms of Da receptors generated by 
alternative splicing of the Da receptor gene, and the mRNA 
levels of 5-HTac receptors were assessed by reverse 
transcription polymerase chain reaction (RT-PCR) using fi- 
actin as an internal standard.
1. Changes of mRNA levels of DA Dat and D3a receptors
As shown in figure 17, the striatal mRNA levels of Dat
receptors in intact and n6-0HDA-lesioned rats receiving 
haloperidol were significantly increased as compared to the 
mRNA levels of rats that were not treated with haloperidol 
(Fig. 17, l.10±0.24 and 1.27±0.26 vs. 0.24±0.04 and
0.36±0.11, P<0.01). However, 8 months after haloperidol 
withdrawal, the mRNA levels of n6-OHDA-lesioned rats 
returned to the level found in controls (Fig. 17, 0.44±0.13, 
P>0.05) . The Dss mRNA levels of nfi-OHDA-lesioned rats, 
regardless of whether haloperidol was administered was 
slightly but not significantly increased when compared to 
other treatment groups (Fig, 17). This may indicate that 
the changes of the D]L subtype of D, receptor is more closely 
associated with the effect of long-term haloperidol 
treatment.
2. Changes of mRNA levels of 5-HT2C receptors
Since 5-HTac receptors have an important role in 
regulating spontaneous oral activity of rats (Gong et al., 
1992), striatal 5-HTac mRNA levels were also assessed in 
our rats. In both groups (intact and n6-0HDA-lesioned rats) 
that received haloperidol treatment, there was a slight but 
not significant increase of 5-HTJC receptor mRNA level (Fig. 
17, 13th and 14th bars vs 11th and 12th bars, P>0.05) .
Eight months after haloperidol withdrawal, the 5-HTac 
receptor mRNA level was slightly reduced as compared to the 
level at the time of haloperidol withdrawal(Fig. 17, 14th 
bar vs 15th bar).
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D. Changes of DA D2 Receptor Binding Parameters
As revealed by [3H]raclopride binding to homogenates of 
rat striatum, chronic haloperidol treatment produced a 
significant increase of Da receptor density (Bawt) in rostral 
striatum of both intact and n6-0HDA-lesioned rats. The Kd 
was not significantly altered. Eight months after 
haloperidol withdrawal, the of n6-0HDA-lesioned rats 
returned to control levels (table 2).
E. Effects of n6-0HDA treatment on the levels of monoamines 
and their metabolites in the striatum
1. DA, DOPAC and HVA levels
Neonatal 6-OHDA treatment produced a marked reduction 
in the content of DA and DA metabolites in rat striatum. DA 
and HVA contents were reduced more than 96% in caudal 
striatum of n6-OHDA-lesioned rats, regardless of haloperidol 
treatment (table 3, PcO.Ol). DOPAC levels in the striata of 
n6-0HDA-lesioned rats were also profoundly reduced (>89%). 
Long-term haloperidol treatment produced a slight (about 
12%) but significant reduction of DA, DOPAC and HVA levels 
in the striatum of intact rats (table 3, P<0.05 or 0.01).
2. 5-HT, 5-HT metabolites and NE levels
Long-term haloperidol treatment per se had no effect on 
striatal 5-HT content in intact and n6-0HDA-lesioned rats 
However, there was a significant elevation of 5-HT content 
in the striatum of n6-0HDA-lesioned rats (table 3, PcO.Ol). 
The content of S-HIAA was significantly increased in the n6-
OHDA-lesioned rats vs. the intact rats, regardless of the 
treatment of haloperidol (table 3). Therefore, n6-0HDA 
treatment significantly increased 5-HT and 5-HIAA contents 
in rat striata, whereas haloperidol had little effect.
There was no changes in the content of NE in the striata of 
the different treatment groups (table 3). This indicates 
that desipramine pretreatment effectively protected 
noradrenergic neurons from nfi-OHDA destruction.
Accordingly, n6-0HDA produced a selective effect on the DA 
system.
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Table 1
Effects of assorted agonists and antagonists on 
spontaneous oral activity of rats during the 8 months 
following termination of long-term haloperidol treatment
Test
Substances
Dose
(mg/kg)
Number of Oral Movement 
After Treatment
Test
Substance vehicle
cyproheptadine 0.3 27.9(5.0) 26.9(4.3)
Ketamine 10.0 27.9(2.8) 28.1(4.6)
Naloxone 1.5 37.7(7.4) 27.0(5.4)
Naloxone 5.0 31.7(3.8) 27.0(5.4)
Theophylline 20.0 32.4(4.2) 24.1(4.5)
Ranitidine 5.0 21.4(4.6) 23.9(4.3)
Phenoxybenzamine 10.0 13.7(2.1) 21.4(4.7)
Propranolol 20.0 24.7(6.2) 27,7(6.9)
Phentolamine 2.0 34.1(4.7) 30.1(5.4)
MK-801 0.3 5.4(2.4) 27.3(4.8)*
Morphine 1.0 33.4(3.5) 29.9(3.2)
Each value represents the mean(S.E.M.) number of vacuous 
chewing movements of 6 to 9 rats. Rats were first observed 
after i.p. or s.c. administration of vehicle, then after 
administration of the test substances. Doses refer to salt 
form of each substance.
*;P<0.01 when compared to vehicle treatment
Table 2
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Effects of n6-OHDA and chonic haloperidol treatment on 
[3H]raclopride binding to rat striatum homogenates
Group Bn^fmol/mg protein) Ka(pM)
nVehicle + tap 
water
203 (174-233)a 657 (492-817)
n6-OHDA+tap water 261 (219-303)b 809 (668-994)
nVehicle + 
Haloperidol 339 (259-418)c 986 (776-1197)
n6-OHDA+
Haloperidol 350 (301-399)“ 895 (822-966)
n6-OHDA+
Haloperidol
(withdrawn)
230 (172-287)* 704 (524-873)
Rats recerved vehicle or 6-OHDA (100 pg each side,
i.c.v., 20 mg/kg desipramine pretreatment, 1 hr) 3 days 
after birth and haloperidol (1.5 mg/kg, via drinking 
water) or tap water from 2 month for an 11 months period. 
Rostral striata were removed 9 days or 8 months after 
withdrawing haloperidol. Saturable curves for striatal 
homogenates were constructed, using binding data (n=5) 
from 10 concentrations of [3H]raclopride (93pM to
8250pM). The and for 3H-raclopride binding was 
determined with a computer program (GraphPad Software, 
Inc., San Diego, CA). Data are expressed as mean (95% 
confidence interval)
a vs. c and a vs. d: PcO.Ol
e vs c and e vs. d: P<0.05
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Effects of neonatal 6-OHDA and chronic haloperidol 
treatment on concentrations of monoamines and 
their metabolites in the striatum
Group n DA DOPAC HVA 5-HT 5-HIAA NE
nVehicle* 
tap water
8 52.8±5.7 7.6±0.9 4.010.2 4.H0.2 5.210.2 l.llO.l
n6-OHDA+ 
tap water
9 1.6±0.5# o.aio.i# O.llO.l# 5.310.2# 6.410.2# 1.010.1
nVehicle*
Hal
8 46.0±3.7* 5.3t0.5* 2.710.3* 4.310.2 5.410.2 1.110.1
n6-OHDA* 
Hal
8 1,9±0.3# 0.6±0.1# 0.110.1# 4.810.3 6.410.2# 1.210.1
Rats were treated at 3 days after birth with 6-OHDA HBr (100 ^g 
each side, i.c.v., salt form; desipramine pretreatment, 1 hr) or 
its vehicle, From 2 months after birth, haloperidol (Hal) was given 
via drinking water (1.5 mg/kg/day, 2 days/week for 1 month, then 
daily for 10 months). Strata were removed for assay 8 or 9 days 
after the withdrawal of haloperidol. Values are mean nanomoles per 
gram of tissue ± S.E.M.. Eight samples from each group was 
detected.
*: p<0.05 and #:p<0.01 when compared to vehicle control group.
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Binding o f pH ]Raclopride to  Rat Striatum.
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Fig.l. Representative saturation curves of [JH]raclopride 
binding to rostral striatal homogenates of rats. Aliquots 
of striatal homogenates were added to a graded series of 10 
concentrations of []H] raclopride (93-0245 pM) . Curves for 
total, specific and nonspecific binding and the values for 
Bmx and Kj were generated by fitting the data to a double 
rectangular hyperbola equation [Y«A*X/(B+X)+C*X/(D+X)+E*X] 
using a computer program (GraphPad Software Inc., San Diego, 
CA) .
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E ffect of Haloperidol Treatment on Spontaneous Oral 
Activity of In tac t and Neonatal 6-OHDA-Lesioned Rats
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Fig.2. Time-course effects of chronic haloperidol treatment 
on spontaneous oral activity of rats. Rats were treated at 
3 days after birth with 6-OHDA HBr (200 /ig,salt form, half 
in each lateral ventricle? desipramine pretreatment, 20 
mg/kg, 1 hr) or vehicle. Haloperidol was added to the 
drinking water starting at 2 months after birth (1.5 
mg/kg/day x 2 days per week for 1 month; then daily for 10 
months). Spontaneous oral activity was observed at 1- or 2- 
week intervals during the 11 months of haloperidol 
administration, in 1-h observation sessions (observation of 
1 min every 10 min for 60 min). Each point represents the 
mean number of spontaneous oral movements for each 
observation. Starting from the 15th week after haloperidol 
treatment, the spontaneous oral activity in both groups of 
rats that received haloperidol was significantly higher than 
before starting treatment (P<0.01). The high oral activity 
in these rats persisted throughout the duration of the 
experiment (n«9).
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E ffec ts  of Prolonged Haloperidol Treatment on Oral. Activity 
of In ta c t and Neonatal 6-OHDA-Lesloned R ats
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Fig.3. Effect of long-term haloperidol treatment on oral 
activity of rats. Rats received the treatments and 
observations as described in fig.2. Bars represent the mean 
number of spontaneous oral movements (±S.E.M.) one week 
before starting haloperidol administration (-1 week, n»9), 6 
months (6 months, n»9) or 11 months (11 months, n-9) after 
haloperidol administration and Q months (19 months, n»7) 
after discontinuing haloperidol.
*,**: Different labeled bars are significantly different 
from each other, P<0.01.
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SKF 38393 Dose-Effect Curves at 12 Weeks of Haloperidol Treatment
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Fig.4. Doae-effect curves for SKF 38393-induced oral 
activity of rats during the 12th week of haloperidol 
administration. Oral activity was observed 10 min after 
administration of SKF 38393 HC1 (abscissa). Each point 
represents the mean number of oral movements (n»9) 
(ordinate).
*: P<0.05 vs. the oral activity induced by vehicle in the
same group
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SKF 38393  D ose-Effect Curves at 
36 Weeks of Haloperidol Treatment
60 o Intact+Tap Water 
•  Intact+HAI
a 6-OHDA+Tap Water 
■ 6-OHDA+HAL
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Fig.5. Dose-effect curves for SKF 38393-induced oral 
activity of rats during 36th week of haloperidol 
administration. Legend ad in fig.4 (n«9)
*: P<0.01 vs. the oral activity induced by vehicle in the
same group
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a-CPP Dose-Effect Curves at 12 Weeks of Haloperidol Treatment
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Fig.6. Dose-effect curves for m-CPP-induced oral activity 
of rats during the 12th week of haloperidol treatment. Oral 
activity was observed 10 min after administration of 
mCPP 2HC1. Legend as in fig. 4 (n»9).
*: P<0.01 vs. the oral activity induced by vehicle in the
same group
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m-CPP Dose-Effect Curves at 
3 8  Weeks of Haloperidol Treatment
80
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fig.7. Dose-effect curves for m-CPP-induced oral activity of 
rats during the 38th week of haloperidol treatment. Legend 
as in fig.4 (n«9).
*: P<0.01 vs. the oral activity induced by vehicle in the 
same group
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Effect of SCH 23390 on Spontaneous Oral Activity
of Rats During Haloperidol Treatment
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Fig.8. SCH 23390 attenuation of spontaneous oral activity 
of rats during haloperidol treatment. Rats received 6-OHDA 
and haloperidol treatment as described in fig. 2. Oral 
activity was observed 10 min after vehicle administration 
(saline, 1.0 ml/kg, i.p.) with or without SCH 23390 HCl (1.0 
mg/kg, i.p., lh) pretreatment . Bars represent the mean (± 
S.E.M,) number of oral movements (n»9).
bars with different labels were significantly 
different from each other (P<0.01).
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E ffec ts  of Mianserin on Oral Activities* 
Induced by SKF 3 8 3 9 3  and m-CPP
□  intact rata + tap watar
Laalonad rata + tap watar
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Fig.9. Effect of mianserin on oral activity induced by SKF 
38393 and m-CPP in rats. Rats received 6-OHDA and 
haloperidol treatments as described in fig. 2. Oral 
activity was observed 10 min after saline (1 ml/kg, i.p.), 
SKF 38393 HCl (1.0 mg/kg, i.p.) or m-CPP 2HC1 (3.0 mg/kg, 
i.p.) challenge with or without mianserin pretreatment (1 
mg/kg, i.p., lh). Bars represent mean (± S.E.M.) number of 
oral movement (n»9).
*: P<0.05 vs. oral activity of the same group pre-treated 
with mianserin
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Effect of Muscimol on Spontaneous Oral Activity
of Rats During Haloperidol Treatment
a) 40
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Fig.10. Effect of muscimol on spontaneous oral activity of 
rats during haloperidol treatment. Rats received 6-OHDA and 
haloperidol treatments as described in fig. 2. Oral 
activity was observed 10 min after vehicle administration 
(saline, 1.0 ml/kg) with or without muscimol (3.0 mg/kg, 
i.p., lh) pretreatment. Bars represent the mean (± S.E.M.) 
number of oral movement (n=9).
**: P<0.01 vs. all other bars
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E ffect of BicuculNne on Spontaneous Oral Activity
of R ats During Haloperidol Treatment
50
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Fig.11. Effect.of bicuculline on spontaneous oral activity 
of rats during haloperidol treatment. Rats received 6-OHDA 
and haloperidol treatments as described in fig. 2. Oral 
activity was observed as described in fig. 10 (n»9). 
Bicuculline did not attenuate the spontaneous oral activity 
of rats (P>0.05).
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Effect of Scopolamine on Spontaneous Oral Activity
of Rats During Haloperidol Treatment
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Pig.12. Effect of acopolamine on spontaneous oral activity 
of rats. Rats received 6-OHDA and haloperidol treatments as 
described in fig. 2. Oral activity was observed 10 min 
after vehicle administration (saline, 1 ml/kg) with or 
without scopolamine HCl (0.1 mg/kg, i.p., lh) pretreatment. 
Bars represent mean (± S.E.M.) number of oral movement 
(n«9) .
*,**: Different labeled bars are significantly different 
from each other.
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S p o n ta n e o u s  Oral Activity of Haloperidol-Withdrawn 
Neonatal  6-OHDA-Lesioned R ats
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Fig.13. Spontaneous oral activity in n6-OHDA-lesioned rats 
after haloperidol withdrawal. The oral activity of n6-0HDA- 
lesioned rats was observed 10 min after injection of saline 
{1 ml/kg, i.p.), each week or in alternate week during 
haloperidol withdrawal. Oral activity of these rats 
remained at an elevated level, similar to that observed 
before haloperidol withdrawal. Each point represents the 
mean (± S.E.M.) number of oral movements (n»S-9),
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Effects of DA Receptor Antagonists on Spontaneous Oral 
Activity of Haloperidol-Withdrawn n6-0HDA-Lesioned Rats
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Fig,14. Effects of DA receptor antagonists on spontaneous 
oral activity of n6-0HDA-lesioned rats after haloperidol 
withdrawal. Oral activity of nfi-OHDA-lesioned rats was 
observed 10 min after vehicle administration (saline, l 
ml/kg, i.p.) with or without pretreatment with a DA 
receptor antagonists SCH 23390 HCl (1.0 mg/kg, i.p, lh), 
spiperone HCl (0.08 mg/kg, i.p., lh) or metoclopramide HCl 
(5.0 mg/kg i.p., lh). Bars represent mean (± S.E.M.) number 
of oral movements (n**7-9) . These DA antagonists did not 
attenuate the spontaneous oral activity of haloperidol- 
withdrawn n6-OHDA-lesioned rats (£>>0.05).
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Effects of 5-HT Receptor Antagonists on Spontaneous Oral 
Activity of Haloperidol-Withdrawn n6-0HDA-lesioned Rats
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Pindolol K etanserin Metoclopramide
Fig.15. Effects of 5-HT receptor antagonists on spontaneous 
oral activity of n6-OHDA-lesioned rats after haloperidol 
withdrawal. Oral activity of n6-OHDA-lesioned rats was 
observed 10 min after vehicle administration (saline, 1 
ml/kg, i.p.) with or without pretreatment with the 5-HT 
antagonists pindolol (3.0 mg/kg, i.p., lh), ketanserin 
tartrate (5.0 mg/kg, i.p., lh) or metoclopramide HCl (5.0 
mg/kg, i.p., lh). Bars represent mean (± S.E.M.) number of 
oral movements (n»S-9). These 5-HT receptor antagonists did 
not attenuate the spontaneous oral activity of haloperidol- 
withdrawn nS-OHDA-lesioned rats (P>0.05).
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E f f e c t  o f Scopolam ine an d  Muscimol on •
S p o n ta n e o u s  Oral Activity o f  Haloperidol-W ithdrawn 
N eonata l 6-O H D A -L esioned  R a ts
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Fig.16. Effects of scopolamine and muscimol on spontaneous 
oral activity of n6-0HDA-lesioned rats after haloperidol 
withdrawal. Oral activity of n6-OHDA-lesioned rats was 
observed 10 min after vehicle administration (saline! l 
ml/kg, i.p.) with or without pretreatment with scopolamine 
HCl (0.1 mg/kg, i.p., lh) or muscimol (3.0 mg/kg, i.p., lh), 
Bars represent mean (± S.E.M.) number of oral movements 
(n»6-9).
*: P<0.05 vs. the oral activity after vehicle stimulation
75
mRNA Levels of D2L, D2S and 5-HT2C Receptors 
in Rat Striatum after Long-Term Haloperidol Treatment 
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fig. 17. Messenger RNA levels of DA DaL, DJS and 5-HTac 
receptors in the striatum of intact and neonatal 6-OHDA- 
lesioned rats after long-term haloperidol treatment. mRNA 
levels were determined by reverse transcriptase polymerase 
chain reaction (RT-PCR). Each bar represents the 
mean(±S.E.M.) number of relative mRNA levels expressed as 
the percentage of fi-actin mRNA (n-6).
+: PcO.OS when compared to the same receptor subtype of
other groups
Chapter 4
Discussion
i
Due to the difficulty in obtaining human tissues for 
investigation and the fact that available patients have 
usually received complex therapeutic regimens, a direct 
neurochemical basis underlying TD is difficult to be derived 
from TD patients (Casey, 1987). Therefore, animal models 
play a significant -role in attempting to determine the 
pathophysiological basis of TD. Growing numbers of 
investigations have sought to develope animal models for TD 
{Crossman, 1987; waddington, 1990). However, diversity, or 
even conflicting results, especially the time of occurrence, 
duration and persistence of spontaneous oral dyskinesias, 
exist in the current animal models of TD. It is important 
to established an animal model that can reproduce the 
phenomenology of TD patients and thereby.give rise to 
evidence related to the etiological alterations of TD 
(Waddington, 1990).
All primate models of TD were developed by long-term 
treatment with neuroleptics such as haloperidol (Gunne and 
Barany, 197G; Gunne et al., 1984) or fluphenazine (Kovacic 
and Domino, 1984; Gunne et al., 1984). Under the treatment 
by haloperidol (1-10 mg per kg, haloperidol decanoate, 3- 
week interval) or fluphenazine (4-10 mg per kg, fluphenazine
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decanoate, 3-week interval) for a period of 1 to 3 years, 
Gunne and associates reported similar symptoms to those of 
TD observed in Cebus apella monkeys. The motor defects 
occured during treatment and persisted in the dyskinetic 
monkeys for 1 to 6 years after cessation of neuroleptics 
(Gunne and Barany, 1976,* Gunne et al., 1984). Kovacic and 
Domino (1984) reported that bi-weekly treatment with 
fluphenazine (0.1-3.2 mg/kg, IM) for 1 year did not produce 
symptoms resembling TD in Cebus apella monkey until a few 
months after the cessation of fluphenazine treatment.
During the period of fluphenazine treatment, all monkeys 
displayed abnormal movements corresponding to the early 
appearing extrapyramidal symptoms of neuroleptic-treated 
patients. These abnormal movements were prevented and 
attenuated by the anticholinergic drug benztropine (0.2-0.6 
mg/kg, IM). The distinct advantage of models developed in 
primates over those in sub-primates is that primate models 
exhibit a physical dyskinesia that is readily recognized. 
Nevertheless, primates react to chronic neuroleptic 
treatments in some aspects in a different way from humans. 
The acute motor abnormality of monkeys to chronic 
neuroleptic treatment and the alleviation of these acute 
reactions by anticholinergic drugs stands in contrast to 
what has been observed in TD patients (Crossman, 1987).
These have led to a criticism of the validity of primate 
models of TD. In addition, the high cost of primates also
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limits the availability of these animals for investigation.
Most studies of TD animal models have been carried out 
in rodents, almost exclusively in rats (for review, see 
Waddington, 1990). All of the current TD animal models were 
produced by long-term administration of neuroleptics such as 
haloperidol, fluphenazine, trifluoperazine and 
metoclopramine to intact rats. The duration of drug 
treatment ranges from 1.5 months to 13 months with durations 
of withdrawal up to 5 months. There were marked 
inconsistencies among the rats models developed by 
comparable treatments. Some studies reported late-onset 
oral movement (Ellison and See, 1989) whereas others 
reported early emergence of similar movement (Rupniak et 
al., 1985a) or even lack of any drug effect (Levy and 
Ellison, 1987), There were also conflicting results 
concerning whether the altered oral activity can persist in 
rats, a phenomenon that is found in TD patients. Although 
it has been reported that oral activity was able to persist 
for up to 2.5 months in trifluoperazine-treated rats 
(Waddington et al., 1983), many other studies reported a 
gradual diminution of oral activity during 2.5 to 5 months 
of drug-withdrawal (Mithani et al., 1987; Gunne and 
Haggstrom, 1983; Gunne et al., 1982). It is difficult to 
draw firm evidence toward the pathophysiology basis of TD 
from current animal models because of the diversity in 
outcomes of the present models. Therefore, an improved TD
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animal model which can appropriately reproduce the 
phenomenology and pathophysiology changes in human is 
urgently needed (Waddington, 1990; Huang and Kostrzewa, 
1994b).
The drugs being administered and the subjects receiving 
such treatment are two major factors in the development of a 
TD animal model (Waddington, 1990). Since neuroleptics 
induce abnormal oral activity in rodents, it is likely that 
rodents and humans response to these drugs in a similar 
manner. Therefore, it appears to be appropriate to 
administer neuroleptics to rats when developing a TD animal 
model. However, TD occurs when neuroleptics are given to 
those human who have already had neuropsychiatric disorders 
rather than to healthy people. Therefore, intact rats may 
not be appropriate subjects for animal models of TD. Some 
factors other than chronic neuroleptic treatment, perhaps 
some extent of central nervous system damage, may 
contribute to the emergence of TD syndromes in either TD 
patients or rats. In fact, more and more evidence suggests 
that central dysfunction contributes to the vulnerability of 
TD (Kane et al., 1985; Owens, 1985; Waddington et al., 1989; 
Waddington, 1990). There are closer associations between 
abnormal orofacial dyskinesias and central dysfunctions 
(such as produced by frontal cortex damage). It was also 
proposed that TD is the result of loss of a discrete 
subpopulation of striatal efferent neurons (probably
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striatonigral) which release GABA as their transmitter 
(Fibiger and Lloyd, 1984). It seemed to us that oral 
dyskinesias are more likely to occur when rats with 
endogenous or exogenous central dysfunctions, are under the 
influence of chronic neuroleptic treatment. Therefore, rats 
with selective central DA neuronal destruction may serve as 
a butter substrate as an animal model for neuroleptic- 
induced tardive dysikinesias.
It is well known that n6-OHDA treatment produces 
supersensitization of DA receptors in rats. In n6-OHDA- 
lesioned rats, doses of L-dihydroxyphenylalanine (L-DOPA), 
SKF 38393 and A77636 [(1R,3S)-3-(1'-adamantyl)-1- 
aminomethyl-3-4-dihydro-5,6-dihydroxy-1H-2-benzopyran)] that 
have little effect on intact rats, produce great changes in 
stereotyped, locomotor or oral activities in n6-OHDA- 
lesioned rats (Breese et al., 1984, 1985a, 1985b; Hamdi and 
Kostrzewa, 1991; Huang and Kostrzewa, 1994a; Kostrzewa,
1993, 1995; Kostrzewa and Brus, 1991). Serotonin 5-HTj 
receptor-mediated oral activity is also enhanced in these 
rats {Gong and Kostrzewa, 1991). In both the earlier DA 
receptor supersensitization hypothesis (Klawans and Hitri, 
1978; Chiu et al., 1981; Crossman, 1987) and the current 
multi-neurotransmitter hypothesis of TD (Waddington, 1990), 
the DA neuronal system is considered to be a major element. 
Because chronic haloperidol treatment and neonatal 6-OHDA 
treatment each sensitize DA receptors in rats, we believed
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that chronic neuroleptic-treated n6-OHDA-lesioned rats would 
represent an improved TD animal model. This provided the 
basis of our study.
Neonatal 6-OHDA treatment markedly decreases the 
striatal content of DA {Breese and Traylor, 1971,1972;
Breese et al., 1984) and elevates 5-HT content (Breese et 
al., 1984; Stachowiak et al., 1984). The findings of our 
study are in agreement with those reports (table 3). There 
is >96% reduction of DA and HVA as well as 89% reduction of 
DOFAC in the caudal striata of the n6-0HDA-lesioned rats, 
regardless of whether rats were treated with haloperidol.
The concentrations of HVA and DOPAC in striatum are slightly 
but significantly reduced in intact rats treated by long­
term haloperidol (table 3). In agreement with the earlier 
report that HVA concentration and tyrosine hydroxylase (THJ 
activity are significantly decreased by chronic (2 mg/kg/day 
for 21 days) haloperidol treatment, reductions in the levels 
of TH activity, DOPAC and HVA concentrations suggest a 
reduced turnover of DA (Rastogi et al., 1982). Rastogi and 
associates (1982) did not find any change in the level of DA 
in striatum in their haloperidol-treated rats, whereas DA 
level in caudal striata of our haloperidol-treated rats was 
significantly reduced. This may due to the differences in 
the length of treatment duration. Meanwhile, as expected, 
the striatal concentration of 5-HT and 5-HIAA were 
significantly elevated by n6-OHDA treatment. The unaltered
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levels of NE in the striatum indicate that selective 
depletion of DA system with n6-0HDA treatment was well- 
achieved by desipramine pretreatment of rats (table 3).
In the present study the incidence of spontaneous oral 
activity in intact and n6-0HDA-lesioned rats remained at 
stable and low levels throughout the entire duration of the 
study. A neonatal 6-OHDA-lesioned per se did not cause a 
significant increase in spontaneous oral activity (Fig.2; 
Fig.3 1st, 2nd, 5th, 6th, 9th and 10th bars). The dose of 
haloperidol (1.5 mg/kg/day) used in this study has been 
shown to produce a plasma haloperidol level equivalent to 
that observed in TD patients (Tamminga et al., 1990). A 
disproportionate increase of spontaneous oral activity 
following chronic haloperidol treatment was found in rats 
lesioned as adults with 6-OHDA (Gunne et al., 1982). There 
were no early emergence of any form of abnormal behavior in 
our rats during haloperidol treatment. However, after 15 
weeks of haloperidol treatment the level of oral activity in 
both intact and 6-OHDA-lesioned rats was markedly increased, 
when compared to the respective base lines of oral activity. 
Chronic haloperidol treatment produced a greater effect in 
n6-0HDA rats vs. intact rats (Fig.2). In the present study, 
when tested during the 12th, 36th and 38th weeks of 
haloperidol treatment, the oral activity of n6-OHDA rats was 
markedly elevated by the DA Dt receptor agonist SKF 38393 
and 5-HT2 receptor agonist m-CPP (Figs. 4-7). These
findings are in agreement with many others (Gong and 
Kostrzewa, 1991; Kostrzewa and Gong, 1991; Huang and 
Kostrzewa, 1994a) and indicate that there is a 
supersensitization of DA D, and 5-HT, receptors that are 
involved in oral response in n6-OHDA-lesioned rats. If the 
process of DA receptor supersensitivity partly accounts for 
increased oral activity in TD patients (Chiu et al., 1981; 
Klawans and Hitri, 1978; Crossman, 1987), the effects 
produced by chronic haloperidol treatment could be either 
additive or synergistic with the receptor sensitization 
produced by a neonatal 6-OHDA lesion. This could account 
for the 2-fold higher oral activity in n6-0HDA-lesioned rats 
vs. intact rats receiving haloperidol (Fig.2 and Fig.3).
The elevated level of oral activity that was induced by 
chronic haloperidol treatment persisted unabated in n6-0HDA- 
lesioned rats during the 8 months after haloperidol 
withdrawal (Fig.13). This is the longest withdrawal period 
that has ever been described in neuroleptic-treated rats. 
Considering the life span of rats, the persistence of 
enhanced oral activity in these rats seems to represent a 
permanent effect, akin to the oral dyskinesia accompanying 
TD in humans. It has been observed that increased oral 
activity persists in about 65% of TD patients, long after 
the cessation of neuroleptic treatment. The greater the 
duration of neuroleptic treatment, the more likely is the 
abnormal oral activity to persist after neuroleptic
withdrawal (Jeste and Wyatt, 1982a/ Kane and Smithe, 1982}. 
The long-live spontaneous oral dyskinesias of our rats 
contrast with the rapid or gradual decay of this behavior in 
intact rats that were withdrawn from haloperidol. In 3 
different strains of rats that received chronic haloperidol 
in tap water at the same daily dose as in the present study 
{1.5 mg/kg/day) there was a rapid decay in the frequency of 
spontaneous oral activity during the first 2 weeks after 
haloperidol withdrawal, to a level about half of that during 
the haloperidol phase {Tamminga et al., 1990). In a similar 
experiment in which haloperidol was administered in tap 
water for 300 days, there was also a rapid decay in 
spontaneous oral activity of rats in the first month after 
haloperidol withdrawal {Gunne et al., 1986). Mithani et al. 
(1987) reported that a similar decay in spontaneous oral 
activity occurred in rats 2-8 weeks following withdrawal 
from haloperidol- decanoate implants. The interval following 
haloperidol withdrawal is an opportune one for testing drugs 
for their potential to attenuate oral dyskinetic behavior. 
There was no decrement in spontaneous oral activity in the 
lesioned rats following haloperidol withdrawal, indicating 
that there is a stable baseline for testing the ability of 
drugs to attenuate spontaneous oral activity. Although 
numerous trials have been carried for drug testing, 
presently no drug have been proven to be both safe and 
effective for TD treatment. In rats the DA Dt receptor
antagonist SCH 23390 (0.01-0.25mg/kg) and DA Da receptor 
antagonist sulpiride (4-100 mg/kg) reduced vacuous chewing 
movements in a dose-dependent manner (Levin et al., 1989).
In monkeys that were withdrawn from chronic haloperidol 
treatment for 1.5 years, chronic SCH 23390 (9 weeks) 
treatment did not change the baseline of oral dyskinesia, 
whereas raclopride (3 weeks) increased the oral activity of 
these monkeys (Lublin et al., 1993). The acute effect of 
SCH 23390 on the oral dyskinesias of these monkeys was 
biphasic. That is, SCH 23390 increased oral activity of 
these monkeys at a low dose (0,02 mg/kg) and reduced their 
oral activity at a high dose (0.2 mg/kg). Raclopride had no 
effect on oral activity of these monkeys (Peacock et al., 
1990). Therefore, the effectiveness of DA receptor 
antagonists on oral dyskinesias is unresolved. In the 
present study, the effect of SCH 23390 on oral activity was 
tested before and after the cessation of haloperidol 
treatment. SCH 23390 (1.0 mg/kg) significantly attenuated 
the oral activity of haloperidol-treated rats before 
haloperidol withdrawal (Fig.8, 5th bar vs. 6th bar, P<0,05; 
7th bar vs. 8th bar, P<0.01) but had no effect after 
haloperidol withdrawal (Fig.14, 1st and 2nd bars). The DA 
Da receptor antagonists spiperone and metoclopramine had no 
effect on oral dyskinesias after haloperidol withdrawal. 
These results may relate to the view that an imbalance of Da 
and Dj receptor sensitivity in favor of Da receptor is
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associated with oral dyskinesia (Peacock.et al., 1990).
The involvement of 5-HT systems in the behavioral 
regulation was described almost 2 decays ago. One of 'the 
earliest reports regarding 5-H and behavior was that a 
distinctive and highly reproducible motor syndrome was 
elicited by 5-H precursors [L-5-hydroxytryptophan (5-HTP) 
and L-tryptophan] (Jacobs, 1976). Patterned motor 
activities such as chewing, biting and licking behaviors are 
associated with 5-H in adult animals (Jacob and Fornal,
1993; Wallis, 1994) . Specifically, 5-Hax and 5-Hac 
receptors are linked to the initiation of motor pattern 
(Cazalets et al., 1992). It was proposed that the major 
function of 5-H neurons in the central nervous system is to 
initiate and modulate motor outputs and to inhibit sensory 
information processing. These functions can be attenuated 
when 5-HT systems are inhibited. Therefore, central 5-H 
systems are important for maintaining continuous output in 
motor systems (Jacob and Fornal, 1993; Wallis, 1994) . It is 
also known that 5-H systems, particularly 5-Hac receptors, 
play important roles in regulating oral activity in rats 
(Gong et al., 1992; Gong and Kostrzewa, 1992; Brus et al., 
1994) . Atypical neuroleptics have higher affinity to 5-H 
receptors and produce much less extrapyramidal side effects 
(such as TD) as compared to classical neuroleptics. 
Therefore, while DA Da receptor blockade may be essential 
for the treatment of psychosis, blockade of 5-HT receptors
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may reduce the incidence of extrapyramidal side effects. It 
is also quite possible that atypical neuroleptics modulate 
DA function via 5-HT3 receptors (Meltzer and Nash, 1991). 
5-HT3 receptor antagonists have been suggested as novel 
neuroleptics with fewer side effects (Leysen et al., 1993).
Presently, in support with our previous findings (Gong 
et al., 1992), we find that the 5-HTiC receptor antagonist 
mianserin attenuates both m-CPP- and SKF 38393-induced oral 
activity in rats before haloperidol withdrawal {Fig.9),
After haloperidol withdrawal, the 5-HTlA/1B receptor 
antagonist pidolol, 5-HTs receptor antagonist ketanserin and 
5-HTj receptor antagonist metoclopramine fail to attenuate 
spontaneous oral activity of the haloperidol-withdrawn rats 
(Fig.15). We had previously found that disruption of 5-HT 
fibers by neonatal 5,7-DHT (5,7-dihydroxytryptamine) 
treatment attenuates SKF 38393- and pilocarpine-induced oral 
activity in n6-0HDA-lesioned rats. It was thereby proposed 
that multiple sites of interactions involvng 5-HT fibers and 
5-HT receptors, take place between 5-HT and DA systems in 
the brain. Drugs acting on 5-HT receptors may be beneficial 
in preventing or attenuating oral dyskinesias in TD patients 
(Brus et al., 1994).
The involvement of central cholinergic systems are also 
known to be involved in regulating oral activity in animals 
(Rupniak et al., i.983, 1985a, 1985b; Salamone et al., 1990; 
Kostrzewa and Neely, 1993). However, the role of
cholinergic drugs on TD is still unclear, in animals, acute 
or co-administration of anticholinergic drug scopolamine 
were found to decrease (Rupniak et al., 1983, 1985a;
Salamone et al., 1990; Steinpreis et al., 1993) or have no 
effect (Stoessel et al., 1989) on oral activity induced by 
chronic neuroleptic treatment. Clinically it was found that 
cholinomimetics are much more effective than cholinolytics 
in reducing the severity of dyskinetic movements of TD. In 
many cases anticholinergic drugs aggravate TD symptoms 
(Jeste and Wyatt, 1982a; Casey, 1987; Klawans and Rubovits, 
1974). It is generally agreed that cholinolytics alleviate 
the early emergence of oral dystonias, while cholinomimetics 
improve the symptoms of late-onset oral dyskinesias (Klawans 
and Rubovits, 1974; waddington, 1990). The response to 
scopolamine has been used as one criterion to assess 
cholinergic involvement in animal models of TD (Klawans and 
Rubovits, 1974; Rupniak et al., 1983; Casey, 1987). With 
this in mind, we tested the effects of scopolamine on the 
oral activity of our rats. Scopolamine significantly 
attenuated the elevated oral activity of haloperidol-treated 
rats during the phase of haloperidol treatment (Fig. 12) but 
had no effect during the phase after haloperidol was 
withdrawn as a treatment (Fig.16). The different responses 
of oral activity to scopolamine and SCH 23390 before and 
after haloperidol withdrawal indicate that different 
neuronal interactions exist before and after the withdrawal
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□£ haloperidol. It is also possible that at the time when 
the effect of scopolamine was tested during the haloperidol 
treatment phase, the nature of oral activity of the rats was 
more closely related to dystonia, and that the oral activity 
after haloperidol withdrawal might more closely represent 
TD.
Data from human and animal studies reveal that GABA 
agonists such as muscimol and progabide are effective in 
diminishing oral dyskinesias. GABA levels in cerebrospinal 
fluid (CSF) were found to be significantly decreased in TD 
patients (Tamminga et al., 1979). When administered to 
neuroleptic-treated and neuroleptic-free TD patients, 
muscimol at an oral dose of 5 to 9 mg consistently 
attenuated involuntary oral movements and improved TD 
symptoms (Tamminga et al., 1979; Cassady et al., 1992).
Acute challenge and co-administration of progabide with 
neuroleptics markedly reduced neuroleptic-induced oral 
dyskinesias (Mithani et al., 1987; Kaneda et al., 1992). 
Intrastriatal injection of muscimol (25 and 50 ng/0.2pg) 
demonstrated that GABAergic inhibition of apomorphine 
(0.2mg/kg, i.v.)-induced oral movement is regionally 
specific. Muscimol injected into the ventral striatum, but 
not the dorsal striatum significantly inhibited oral 
movement induced by apomorphine (KiKuchi de Beltran et al., 
1993). Although it is difficult to separate the 
antidyskinetic effects of GABA agonists from their sedative
and muscle relaxant effects and there is still no convincing 
evidence to suggest that GABA agonists exert a specific 
antidyskinetic effect (Jeste and Wyatt, 1982a), the 
involvement of impaired GABAergic mechanisms in TD have been 
widely accepted (Mithani et al., 1987; Cassady et al.,
1992). In the present study, the GABA agonist muscimol, at 
a dose of 3.0 kg/mg, significantly attenuated oral activity 
during and after haloperidol treatment. In contrast, 
bicuculline, a GABA receptor antagonist, does not have any 
effect on the oral activity of haloperidol-treated rats 
(Fig.10; Fig.11 and Fig.16).
Other neuronal systems such as opioid (Cancela et al., 
1988; Patrick et al., 1993) and neurokinin systems (Liminga,
1993) have been reported to be involved in the regulation of 
oral activity. With this in mind we tested a variety of 
agents acting at different neuronal systems. As listed in 
table l, no significant effect on oral activity was found 
with adrenergic receptor antagonists phenoxybenzamine (a), 
phentolamine (a) and propranolol (S), or histamine receptor 
antagonists cyproheptadine (HJ and ranitidine (Ha), or NMDA 
(N-methyl-D-asparate) receptor antagonist (ketamine), 
adenosine receptor antagonist (theophylline), opioid 
receptor antagonist (naloxone) and agonist (morphine). The 
NMDA receptor antagonist MK-801 significant reduced the oral 
activity of the rats. However, severe sedation and 
immobility were also observed in these rats. This may mask
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the effect of MK-801 on oral activity. Therefore, it is 
unlikely that these systems had a prominent role in 
regulating oral activity of rats.
Chronic treatment with neuroleptics was shown to cause 
a reversible increase in the B,w for DA Da receptors in rat 
striatum {Duncan et al., 1987; Marin and Chase, 1993; 
Laruelle, et al., 1992). Clow et al. (1980) reported an 
increased Bnax and Kd for DA Da receptors in rat striatum and 
mesolimbic area after chronic trifluoperazine treatment,
The increased Bnax and Ka persisted for 3 months and 2 weeks 
respectively after neuroleptic withdrawal. Dewey and 
Fibiger {1983) similarly reported that the elevated BBMt for 
DA D3 receptors induced by chronic neuroleptic treatment, 
returned to the control level 6 weeks after cessation of 
neuroleptic. Chronic neuroleptic treatment also increased 
DA D3 density in rat caudate putamen {Jiang et al., 1990;
See et al., 1989). The increase of D, receptor density in 
rat striatum and caudate putamen was dissociated from DA 
agonist-induced behavioral supersensitivity {Marin and 
Chase, 1993; Jiang et al., 1990). There are conflicting 
reports regarding neuroleptic-induced alterations in the 
for DA Da receptors in other parts of brain. Rupniak et al. 
(1985b) found that DA Da receptors in nucleus accumbens 
(mesolimbic system) are no longer blocked after 3-6 months 
of neuroleptic treatment. However, Laruelle and associates 
found similar changes of Da receptor binding parameters in
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both rat striatum and nucleus accumbens (Laruelle et al., 
1992) . Neonatal 6-OHDA treatment (bilateral icv, 50 fig each 
side) at 3 days after birth was reported to increase 
[JH]raclopride binding to the substantia nigra, all parts of 
the caudal striatum and most parts of rostral striatum 
(Radja et al,, 1993). In contrast, intrastriatal injection 
of 6-OHDA (4, 6 or 20 fig, each side) at 0 to 2 days after 
birth did not cause significant changes in DA Da receptor 
binding characteristics in rat striatum. The lack of change 
of DA Da receptors may be due to the absence of DA Da 
receptors in the striatum at the time in ontogeny when rats 
were lesioned (Neal and Joyce, 1992; Neal-Beliveau and 
Joyce, 1993). Duncan and colleagues (1987) reported that 15 
days of chronic haloperidol treatment caused a significant 
increase in the for DA Da receptors in nucleus accumbens 
of intact and adult 6-OHDA-lesioned rats but not in n6-OHDA- 
lesioned rats. In the striatum, this treatment also led to 
a significant increase of Bw  in intact and adult 6-OHDA- 
lesioned rats. However, changes in the B„* for DA Da 
receptors in the striatum of n6-0HDA-lesioned rats was not 
determined in their study (Duncan et al., 1987). In our 
study (table 2), in agreement with the previous findings, DA 
Da receptor density (B„J was significantly increased in the 
intact rats receiving chronic haloperidol treatment while K4 
was not significantly altered. Neonatal 6-OHDA treatment 
itself does not cause any change in DA Da binding
parameters. However, there is a marked increase of the 
for DA Da receptors in the striatum of n6-0HDA-lesioned rats 
receiving haloperidol. This finding conflicts with the 
report in which the Bw  for DA Da receptors was found to be 
unaltered in the nucleus accumbent of nG-OHDA-lesioned rats 
after 15 days of haloperidol treatment (Duncan et al.,
1987} . The reason for this apparent discrepancy is unknown. 
However, chronic neuroleptic-induced upregulation of Da 
receptors in nucleus accumbens is transient. DA Da receptor 
density increased temporary and returned to control level in 
3-9 months after starting chronic neuroleptic treatment 
(Clow et al., 1980; Rupniak et al., 1985b). Eight months 
after haloperidol withdrawal, the B^* for striatal DA Da 
recepors in n6-OHDA-lesioned haloperidol-treated rats is at 
control levels whereas the elevated spontaneous oral 
activity still persists (table 2). These results support 
the view that behavioral changes in haloperidol-treated rats 
is dissociated from changes in DA Da receptor number (Jiang 
et al., 1990; Marin and Chase, 1993).
The molecular basis of DA Da receptor upregulation 
after chronic haloperidol has been studied by many 
investigators. It is generally accepted that chronic 
neuroleptic treatment increases the number of DA Da 
receptors in the brain (Creese and Fraser, 1987). In most 
studies chronic haloperidol treatment increased striatal 
mRNA of DA Da receptors (Bernard et al., 1991; Buckland et
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al., 1992; Jaber et al., 1994) although it has also been 
reported that chronic neuroleptic treatment did not 
influence the mRNA of DA D, receptors (Van Tol et al.,
1990) .
The DA Da receptor gene gives rise to two variants of 
mRNA by alternate splicing. These two variants of mRNA code 
for two Da receptor isoforms termed DaL and D,s, with 
sequences of 444 and 415 amino acids respectively. DaL 
protein has 29 more animo acids than Das in the third 
intracellular loop of the receptor (Giros et al., 1989; 
Monsma et al., 1989; Selbie et al., 1989; Martres et al., 
1992) . These two isoforms have the same ligand-binding 
properties but it has been proposed that they may be coupled 
differently to G proteins in signal transduction processes 
(Monsma et al., 1989). It was reported that 16 days (4mg/kg 
per day, i.p.) or 32 days (1.5 mg/kg/injection, i.p. twice a 
day) treatment of haloperidol significantly increased 
striatal mRNA levels of both DaL and Dafl receptors (Fishburn 
et al., 1994; Buckland et al., 1993). Rogue and associates 
reported an increase of striatal total Da and DaL receptor 
mRNA levels after chronic haloperidol treatment (Rogue et 
al., 1991). In contrast, Srivastava et al.(1990) reported 
no change in Da and Datl receptor mRNA levels of rat striatum 
after chronic haloperidol treatment. Similarly, both 
striatal DaL and Da9 receptor mRNA levels were found 
unaltered after chronic haloperidol (Matsunaga et al.,
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1990). Therefore, the increase of mRNA levels may not be 
critical for Da receptor up-regulation after long-term 
haloperidol. It is possible that post-transcriptional 
mechanisms regulate the haloperidol-induced increase of Da 
receptor numbers (Srivistava et al., 1990). In our study, 
in agreement with what was reported by Rogue and colleagues 
(1991), we found that long-term haloperidol treatment 
increased the mRNA levels of DJti receptors in both intact 
and n6-0HDA-lesioned rats whereas Daa receptor mRNA levels 
remained unchanged (Pig. 17}. These findings imply that 
different transcriptional mechanisms regulate the expression 
of mRNA for two Da isoforms under the influence of chronic 
haloperidol treatment. The mechanism underlying this 
regulation is yet to be determined.
A change in 5-HT receptor mRNAs after chronic 
haloperidol treatment has not been reported. Because of the 
interactions between central DA and 5-HT receptors, 
especially 5-HTac receptors (Gong et al., 1992; Brus et al., 
1994), we determined the levels of 5-HTac receptor mRNA in 
all rats after haloperidol treatment. Levels of 5-HTac mRNA 
were slightly but not significantly increased in both groups 
of rats receiving haloperidol, as compared to the rats 
without haloperidol treatment and the rats withdrawn from 
haloperidol (Fig. 17). Our findings suggest that the 
interactions of DA and 5-HT systems in regulating oral 
activity under chronic haloperidol treatment are not at the
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transcriptional level. It is possible that the interactions 
at post-transcriptional or receptor levels contribute to the 
cross-talk of these two systems.
The present study utilized for the first time, chronic 
haloperidol-treated n6-0HDA-lesioned rats as an animal model 
of TD. Long-term haloperidol treatment produces a greater 
incidence of oral dyskinesias in n6-0HDA-lesioned rats vs. 
intact rats. Higher densities of DA D, receptors and 
increased DA DJt, receptor mRNA levels in rostral striatum 
were found in all rats that were treated by haloperidol. 
Eight months after discontinuing haloperidol, the elevated 
D, receptor densities and D3L receptor mRNA levels returned 
to control levels whereas the oral dyskinesia still 
persisted. The dissociation of oral dyskinesia, Da receptor 
density and mRNA levels indicates that Da receptor 
upregulation is not important for the occurrence of oral 
dyskinesias. Instead, oral dyskinesias appear to be related 
to an imbalance of multineuronal systems. An advantage of 
the present model of TD is the persistence of a stable 
elevated baseline of oral activity after haloperidol 
withdrawal, providing a means for dose-response testing and 
even retesting of agents that have the potential to 
attenuate dyskinetic oral activity.
Chapter 5 
Summary
The finding of the present study are summarized as
following:
a. Chronic haloperidol treatment produced a greater 
incidence of oral activity on neonatal 6-OHDA-lesioned 
rats vs. intact rats.
b. The elevated oral activity in n-60HDA-lesioned rats 
persisted for at least 8 months after withdrawal of 
haloperidol treatment.
c. The interval during haloperidol withdrawal is useful 
for studying potential-useful drugs for treatment of 
TD.
d. Chronic haloperidol treatment significantly increased 
dopamine DaL
receptor mRNA levels in rostral striatum of both intact 
and neonatal 6-OHDA-lesioned rats.
e. Chronic haloperidol treatment significantly increased 
dopamine Da receptor density but not affinity in 
rostral striatum of both intact and neonatal 6-0HDA- 
lesioned rats.
d. The increase of D3 density and D3t mRNA returned to 
control level after 8 months of haloperidol 
termination.
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